Abstract
The treatment of patients poisoned with drugs and pharmaceuticals can be quite challenging. Diverse exposure circumstances, varied clinical presentations, unique patient-specific factors, and inconsistent diagnostic and therapeutic infrastructure support, coupled with relatively few definitive antidotes, may complicate evaluation and management. The historical approach to poisoned patients (patient arousal, toxin elimination, and toxin identification) has given way to rigorous attention to the fundamental aspects of basic life suppport — airway management, oxygenation and ventilation, circulatory competence, thermoregulation, and substrate availability. Selected patients may benefit from methods to alter toxin pharmacokinetics to minimize systemic, target organ, or tissue compartment exposure (either by decreasing absorption or increasing elimination). These may include syrup of ipecac, orogastric lavage, activated single- or multi-dose charcoal, whole bowel irrigation, endoscopy and surgery, urinary alkalinization, saline diuresis, or extracorporeal methods (hemodialysis, charcoal hemoperfusion, continuous venovenous hemofiltration, and exchange transfusion). Pharmaceutical adjuncts and antidotes may be useful in toxicant-induced hyperthermias. In the context of analgesic, anti-inflammatory, anticholinergic, anticonvulsant, antihyperglycemic, antimicrobial, antineoplastic, cardiovascular, opioid, or sedative-hypnotic agents overdose, N-acetylcysteine, physostigmine, l-carnitine, dextrose, octreotide, pyridoxine, dexrazoxane, leucovorin, glucarpidase, atropine, calcium, digoxin-specific antibody fragments, glucagon, high-dose insulin euglycemia therapy, lipid emulsion, magnesium, sodium bicarbonate, naloxone, and flumazenil are specifically reviewed. In summary, patients generally benefit from aggressive support of vital functions, careful history and physical examination, specific laboratory analyses, a thoughtful consideration of the risks and benefits of decontamination and enhanced elimination, and the use of specific antidotes where warranted. Data supporting antidotes effectiveness vary considerably. Clinicians are encouraged to utilize consultation with regional poison centers or those with toxicology training to assist with diagnosis, management, and administration of antidotes, particularly in unfamiliar cases.
Keywords: Activate Charcoal, Malignant Hyperthermia, Lipid Emulsion, Activate Charcoal, Clin Toxicol
References
- 1.Wax P.M. Analeptic use in clinical toxicology: A historical appraisal. J Toxicol Clin Toxicol. 1997;35:203–209. doi: 10.3109/15563659709001195. [DOI] [PubMed] [Google Scholar]
- 2.Jones A.W., Dooley J., Murphy J.R. Treatment of choice in barbiturate poisoning; series of twenty-nine cases of barbiturate poisoning treated with pentylenetetrazole (metrazol) and supportive therapy. J Am Med Assoc. 1950;143:884–888. doi: 10.1001/jama.1950.02910450024007. [DOI] [PubMed] [Google Scholar]
- 3.Orwin A., Sim M., Waterhouse J.A.H. A study of the anti-barbiturate effects of bemegride. Br J Psychiatry. 1965;111:531–533. doi: 10.1192/bjp.111.475.531. [DOI] [Google Scholar]
- 4.Hirsh K., Wang S.C. Respiratory stimulant effects of ethamivan and picrotoxin. J Pharmacol Exp Ther. 1975;193:657–663. [PubMed] [Google Scholar]
- 5.Bickerman H.A., Chusid E.L. The case against the use of respiratory stimulants. Chest. 1970;58:53–56. doi: 10.1378/chest.58.1.53. [DOI] [PubMed] [Google Scholar]
- 6.Wolfson B., Siker E.S., Ciccarelli H.E. A double blind comparison of doxapram, ethamivan and methylphenidate. Am J Med Sci. 1965;249:391–398. doi: 10.1097/00000441-196504000-00004. [DOI] [PubMed] [Google Scholar]
- 7.Rappolt R.T.S., Gay G.R., Decker W.J., Inaba D.S. NAGD regimen for the coma of drug-related overdose. Ann Emerg Med. 1980;9:357–363. doi: 10.1016/S0196-0644(80)80112-0. [DOI] [PubMed] [Google Scholar]
- 8.Nattel S., Bayne L., Ruedy J. Physostigmine in coma due to, drug overdose. Clin Pharmacol Ther. 1979;25:96–102. doi: 10.1002/cpt197925196. [DOI] [PubMed] [Google Scholar]
- 9.Zvosec D.L., Smith S.W., Litonjua R., Westfal R.E. Physostigmine for γ-hydroxybutyrate coma: Inefficacy, adverse events, and review. Clin Toxicol. 2007;45:261–265. doi: 10.1080/15563650601072159. [DOI] [PubMed] [Google Scholar]
- 10.Hoffman R.S., Goldfrank L.R. The poisoned patient with altered consciousness. Controversies in the use of a ‘coma cocktail’. J Am Med Assoc. 1995;274:562–569. doi: 10.1001/jama.274.7.562. [DOI] [PubMed] [Google Scholar]
- 11.Anonymous Practical pharmacology. XXIV. J Am Med Assoc. 1915;64:2063–2067. [Google Scholar]
- 12.Temple W.A., Smith N.A., Beasley M. Management of oil of citronella poisoning. J Toxicol Clin Toxicol. 1991;29:257–262. doi: 10.3109/15563659109038618. [DOI] [PubMed] [Google Scholar]
- 13.Sheffield P. Emetics, cathartics, and gastric lavage. Pediatr Rev. 2008;29:214–215. doi: 10.1542/pir.29-6-214. [DOI] [PubMed] [Google Scholar]
- 14.Fantus B. Fullers earth; its absorptive power, and its antidotal value for alkaloids. J Am Med Assoc. 1915;64:1838–1845. [Google Scholar]
- 15.Alpert J.J., Lovejoy F.H., Jr Management of acute childhood poisoning. Curr Probl Pediatr. 1971;1:1–40. doi: 10.1016/S0045-9380(71)80005-1. [DOI] [PubMed] [Google Scholar]
- 16.Clemmesen C., Nilsson E. Therapeutic trends in the treatment of barbiturate poisoning. The Scandinavian method. Clin Pharmacol Ther. 1961;2:220–229. doi: 10.1002/cpt196122220. [DOI] [PubMed] [Google Scholar]
- 17.Lawson A.A., Mitchell I. Patients with acute poisoning seen in a general medical unit (1960–71) Br Med J. 1972;4:153–156. doi: 10.1136/bmj.4.5833.153. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Beaubien A.R., Carpenter D.C., Mathieu L.F., MacConaill M., Hrdina P.D. Antagonism of imipramine poisoning by anticonvulsants in the rat. Toxicol Appl Pharmacol. 1976;38:1–6. doi: 10.1016/0041-008X(76)90154-X. [DOI] [PubMed] [Google Scholar]
- 19.Callaham M., Schumaker H., Pentel P. Phenytoin prophylaxis of cardiotoxicity in experimental amitriptyline poisoning. J Pharmacol Exp Ther. 1988;245:216–220. [PubMed] [Google Scholar]
- 20.Sechi G., Serra A. Wernicke’s encephalopathy: New clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6:442–455. doi: 10.1016/S1474-4422(07)70104-7. [DOI] [PubMed] [Google Scholar]
- 21.Sporer K.A., Khayam-Bashi H. Acetaminophen and salicylate serum levels in patients with suicidal ingestion or altered mental status. Am J Emerg Med. 1996;14:443–446. doi: 10.1016/S0735-6757(96)90146-1. [DOI] [PubMed] [Google Scholar]
- 22.Ashbourne J.F., Olson K.R., Khayam-Bashi H. Value of rapid screening for acetaminophen in all patients with intentional drug overdose. Ann Emerg Med. 1989;18:1035–1038. doi: 10.1016/S0196-0644(89)80925-4. [DOI] [PubMed] [Google Scholar]
- 23.Cooper G.M., Le Couteur D.G., Richardson D., Buckley N.A. A randomized clinical trial of activated charcoal for the routine management of oral drug overdose. QJM. 2005;98:655–660. doi: 10.1093/qjmed/hci102. [DOI] [PubMed] [Google Scholar]
- 24.Karim A., Ivatts S., Dargan P., Jones A. How feasible is it to conform to the European guidelines on administration of activated charcoal within one hour of an overdose? Emerg Med J. 2001;18:390–392. doi: 10.1136/emj.18.5.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Krenzelok E.P., McGuigan M., Lheur P. Position statement: Ipecac syrup. J Toxicol Clin Toxicol. 1997;35:699–709. doi: 10.3109/15563659709001223. [DOI] [PubMed] [Google Scholar]
- 26.Saetta J.P., March S., Gaunt M.E., Quinton D.N. Gastric emptying procedures in the self-poisoned patient: Are we forcing gastric content beyond the pylorus. J R Soc Med. 1991;84:274–276. doi: 10.1177/014107689108400510. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Saetta J.P., Quinton D.N. Residual gastric content after gastric lavage and ipecacuanha-induced emesis in self-poisoned patients: An endoscopic study. J R Soc Med. 1991;84:35–38. doi: 10.1177/014107689108400113. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Saincher A., Sitar D.S., Tenenbein M. Efficacy of ipecac during the first hour after drug ingestion in human volunteers. J Toxicol Clin Toxicol. 1997;35:609–615. doi: 10.3109/15563659709001241. [DOI] [PubMed] [Google Scholar]
- 29.Lapatto-Reiniluoto O., Kivisto K.T., Neuvonen P.J. Gastric decontamination performed 5 min after the ingestion of temazepam, verapamil and moclobemide: Charcoal is superior to lavage. Br J Clin Pharmacol. 2000;49:274–278. doi: 10.1046/j.1365-2125.2000.00138.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Grierson R., Green R., Sitar D.S., Tenenbein M. Gastric lavage for liquid poisons. Ann Emerg Med. 2000;35:435–439. [PubMed] [Google Scholar]
- 31.Tenenbein M., Cohen S., Sitar D.S. Efficacy of ipecac-induced emesis, orogastric lavage, and activated charcoal for acute drug overdose. Ann Emerg Med. 1987;16:838–841. doi: 10.1016/S0196-0644(87)80518-8. [DOI] [PubMed] [Google Scholar]
- 32.Vale J.A., Kulig K. Position paper: Gastric lavage. J Toxicol Clin Toxicol. 2004;42:933–943. doi: 10.1081/CLT-200045006. [DOI] [PubMed] [Google Scholar]
- 33.Sato R.L., Wong J.J., Sumida S.M., Marn R.Y., Enoki N.R., Yamamoto L.G. Efficacy of superactivated charcoal administered late (3 hours) after acetaminophen overdose. Am J Emerg Med. 2003;21:189–191. doi: 10.1016/S0735-6757(02)42251-6. [DOI] [PubMed] [Google Scholar]
- 34.Christophersen A.B., Levin D., Hoegberg L.C., Angelo H.R., Kampmann J.P. Activated charcoal alone or after gastric lavage: A simulated large paracetamol intoxication. Br J Clin Pharmacol. 2002;53:312–317. doi: 10.1046/j.0306-5251.2001.01568.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Alaspaa A.O., Kuisma M.J., Hoppu K., Neuvonen P.J. Out-of-hospital administration of activated charcoal by emergency medical services. Ann Emerg Med. 2005;45:207–212. doi: 10.1016/j.annemergmed.2004.07.448. [DOI] [PubMed] [Google Scholar]
- 36.Adams B.K., Mann M.D., Aboo A., Isaacs S., Evans A. Prolonged gastric emptying half-time and gastric hypomotility after drug overdose. Am J Emerg Med. 2004;22:548–554. doi: 10.1016/j.ajem.2004.08.017. [DOI] [PubMed] [Google Scholar]
- 37.Green R., Sitar D.S., Tenenbein M. Effect of anticholinergic drugs on the efficacy of activated charcoal. J Toxicol Clin Toxicol. 2004;42:267–272. doi: 10.1081/CLT-120037426. [DOI] [PubMed] [Google Scholar]
- 38.Auerbach P.S., Osterloh J., Braun O., Hu P., Geehr E.C., Kizer K.W., McKinney H. Efficacy of gastric emptying: Gastric lavage versus emesis induced with ipecac. Ann Emerg Med. 1986;15:692–698. doi: 10.1016/S0196-0644(86)80427-9. [DOI] [PubMed] [Google Scholar]
- 39.Albertson T.E., Derlet R.W., Foulke G.E., Minguillon M.C., Tharratt S.R. Superiority of activated charcoal alone compared with ipecac and activated charcoal in the treatment of acute toxic ingestions. Ann Emerg Med. 1989;18:56–59. doi: 10.1016/S0196-0644(89)80314-2. [DOI] [PubMed] [Google Scholar]
- 40.Kulig K., Bar-Or D., Cantrill S.V., Rosen P., Rumack B.H. Management of acutely poisoned patients without gastric emptying. Ann Emerg Med. 1985;14:562–567. doi: 10.1016/S0196-0644(85)80780-0. [DOI] [PubMed] [Google Scholar]
- 41.Comstock E.G., Boisaubin E.V., Comstock B.S., Faulkner T.P. Assessment of the efficacy of activated charcoal following gastric lavage in acute drug emergencies. J Toxicol Clin Toxicol. 1982;19:149–165. doi: 10.3109/15563658208990377. [DOI] [PubMed] [Google Scholar]
- 42.Pond S.M., Lewis-Driver D.J., Williams G.M., Green A.C., Stevenson N.W. Gastric emptying in acute overdose: A prospective randomised controlled trial. Med J Aust. 1995;163:345–349. doi: 10.5694/j.1326-5377.1995.tb124625.x. [DOI] [PubMed] [Google Scholar]
- 43.Bosse G.M., Barefoot J.A., Pfeifer M.P., Rodgers G.C. Comparison of three methods of gut decontamination in tricyclic antidepressant overdose. J Emerg Med. 1995;13:203–209. doi: 10.1016/0736-4679(94)00153-7. [DOI] [PubMed] [Google Scholar]
- 44.Kirshenbaum L.A., Mathews S.C., Sitar D.S., Tenenbein M. Whole-bowel irrigation versus activated charcoal in sorbitol for the ingestion of modified-release pharmaceuticals. Clin Pharmacol Ther. 1989;46:264–271. doi: 10.1038/clpt.1989.137. [DOI] [PubMed] [Google Scholar]
- 45.Mayer A.L., Sitar D.S., Tenenbein M. Multiple-dose charcoal and whole-bowel irrigation do not increase clearance of absorbed salicylate. Arch Intern Med. 1992;152:393–396. doi: 10.1001/archinte.152.2.393. [DOI] [PubMed] [Google Scholar]
- 46.Lee M.R. Ipecacuanha: The South American vomiting root. J R Coll Physicians Edinb. 2008;38:355–360. [PubMed] [Google Scholar]
- 47.Manno B.R., Manno J.E. Toxicology of ipecac: A review. Clin Toxicol. 1977;10:221–242. doi: 10.3109/15563657708987968. [DOI] [PubMed] [Google Scholar]
- 48.Krenzelok E.P., Dean B.S. Effectiveness of 15-mL versus 30-mL doses of syrup of ipecac in children. Clin Pharm. 1987;6:715–717. [PubMed] [Google Scholar]
- 49.Yamashita M., Yamashita M., Azuma J. Urinary excretion of ipecac alkaloids in human volunteers. Vet Hum Toxicol. 2002;44:257–259. [PubMed] [Google Scholar]
- 50.Anonymous Position paper: Ipecac syrup. J Toxicol Clin Toxicol. 2004;42:133–143. doi: 10.1081/CLT-120037421. [DOI] [PubMed] [Google Scholar]
- 51.Garrison J., Shepherd G., Huddleston W.L., Watson W.A. Evaluation of the time frame for home ipecac syrup use when not kept in the home. J Toxicol Clin Toxicol. 2003;41:217–221. doi: 10.1081/CLT-120021101. [DOI] [PubMed] [Google Scholar]
- 52.American Academy of Pediatrics Committee on Injury, Violence, and. Poison Prevention Poison treatment in the home. Pediatrics. 2003;112:1182–1185. doi: 10.1542/peds.112.5.1182. [DOI] [PubMed] [Google Scholar]
- 53.Bond G.R. Home syrup of ipecac use does not reduce emergency department use or improve outcome. Pediatrics. 2003;112:1061–1064. doi: 10.1542/peds.112.5.1061. [DOI] [PubMed] [Google Scholar]
- 54.MacLean W.C., Jr A comparison of ipecac syrup and apomorphine in the immediate treatment of ingestion of poisons. J Pediatr. 1973;82:121–124. doi: 10.1016/S0022-3476(73)80029-0. [DOI] [PubMed] [Google Scholar]
- 55.Dorrington C.L., Johnson D.W., Brant R. The frequency of complications associated with the use of multiple-dose activated charcoal. Ann Emerg Med. 2003;41:370–377. doi: 10.1067/mem.2003.86. [DOI] [PubMed] [Google Scholar]
- 56.Caravati E.M., Knight H.H., Linscott M.S., Jr, Stringham J.C. Esophageal laceration and charcoal mediastinum complicating gastric lavage. J Emerg Med. 2001;20:273–276. doi: 10.1016/S0736-4679(01)00282-7. [DOI] [PubMed] [Google Scholar]
- 57.Mofredj A., Rakotondreantoanina J.R., Farouj N. Severe hypernatremia secondary to gastric lavage. Ann Fr Anesth Reanim. 2000;19:219–220. doi: 10.1016/s0750-7658(00)00210-0. [DOI] [PubMed] [Google Scholar]
- 58.Roberts J.R., Gracely E.J., Schoffstall J.M. Advantage of high-surface-area charcoal for gastrointestinal decontamination in a human acetaminophen ingestion model. Acad Emerg Med. 1997;4:167–174. doi: 10.1111/j.1553-2712.1997.tb03735.x. [DOI] [PubMed] [Google Scholar]
- 59.Chyka P.A., Seger D., Krenzelok E.P., Vale J.A. Position paper: Single-dose activated charcoal. Clin Toxicol. 2005;43:61–87. doi: 10.1081/clt-200051867. [DOI] [PubMed] [Google Scholar]
- 60.Neuvonen P.J. Clinical pharmacokinetics of oral activated charcoal in acute intoxications. Clin Pharmacokinet. 1982;7:465–489. doi: 10.2165/00003088-198207060-00001. [DOI] [PubMed] [Google Scholar]
- 61.Spiller H.A., Winter M.L., Klein-Schwartz W., Bangh S.A. Efficacy of activated charcoal administered more than four hours after acetaminophen overdose. J Emerg Med. 2006;30:1–5. doi: 10.1016/j.jemermed.2005.02.019. [DOI] [PubMed] [Google Scholar]
- 62.Buckley N.A., Whyte I.M., O’Connell D.L., Dawson A.H. Activated charcoal reduces the need for N-acetylcysteine treatment after acetaminophen (paracetamol) overdose. J Toxicol Clin Toxicol. 1999;37:753–757. doi: 10.1081/CLT-100102452. [DOI] [PubMed] [Google Scholar]
- 63.Berg M.J., Berlinger W.G., Goldberg M.J., Spector R., Johnson G.F. Acceleration of the body clearance of phenobarbital by oral activated charcoal. N Engl J Med. 1982;307:642–644. doi: 10.1056/NEJM198209093071102. [DOI] [PubMed] [Google Scholar]
- 64.Berlinger W.G., Spector R., Goldberg M.J., Johnson G.F., Quee C.K., Berg M.J. Enhancement of theophylline clearance by oral activated charcoal. Clin Pharmacol Ther. 1983;33:351–354. doi: 10.1038/clpt.1983.44. [DOI] [PubMed] [Google Scholar]
- 65.Levy G. Gastrointestinal clearance of drugs with activated charcoal. N Engl J Med. 1982;307:676–678. doi: 10.1056/NEJM198209093071109. [DOI] [PubMed] [Google Scholar]
- 66.American Academy of Clinical Toxicology. European Association of Poisons Centres and. Clinical Toxicologists Position statement and practice guidelines on the use of multi-dose activated charcoal in the treatment of acute poisoning. J Toxicol Clin Toxicol. 1999;37:731–751. doi: 10.1081/CLT-100102451. [DOI] [PubMed] [Google Scholar]
- 67.Campbell J.W., Chyka P.A. Physicochemical characteristics of drugs and response to repeat-dose activated charcoal. Am J Emerg Med. 1992;10:208–210. doi: 10.1016/0735-6757(92)90210-O. [DOI] [PubMed] [Google Scholar]
- 68.Pond S.M., Olson K.R., Osterloh J.D., Tong T.G. Randomized study of the treatment of phenobarbital overdose with repeated doses of activated charcoal. J Am Med Assoc. 1984;251:3104–3108. doi: 10.1001/jama.251.23.3104. [DOI] [PubMed] [Google Scholar]
- 69.Swartz C.M., Sherman A. The treatment of tricyclic antidepressant overdose with repeated charcoal. J Clin Psychopharmacol. 1984;4:336–340. doi: 10.1097/00004714-198412000-00008. [DOI] [PubMed] [Google Scholar]
- 70.De Silva H.A., Fonseka M.M., Pathmeswaran A., Alahakone D.G., Ratnatilake G.A., Gunatilake S.B., Ranasinha C.D., Lalloo D.G., Aronson J.K., de Silva H.J. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: A single-blind, randomised, placebo-controlled trial. Lancet. 2003;361:1935–1938. doi: 10.1016/S0140-6736(03)13581-7. [DOI] [PubMed] [Google Scholar]
- 71.Eddleston M., Juszczak E., Buckley N.A., Senarathna L., Mohamed F., Dissanayake W., Hittarage A., Azher S., Jeganathan K., Jayamanne S., Sheriff M.R., Warrell D.A. Multiple-dose activated charcoal in acute self-poisoning: A randomised controlled trial. Lancet. 2008;371:579–587. doi: 10.1016/S0140-6736(08)60270-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Olkkola K.T. Effect of charcoal-drug ratio on antidotal efficacy of oral activated charcoal in man. Br J Clin Pharmacol. 1985;19:767–773. doi: 10.1111/j.1365-2125.1985.tb02712.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Hoegberg L.C., Angelo H.R., Christophersen A.B., Christensen H.R. The effect of food and ice cream on the adsorption capacity of paracetamol to high surface activated charcoal: In vitro studies. Pharmacol Toxicol. 2003;93:233–237. doi: 10.1046/j.1600-0773.2003.pto930506.x. [DOI] [PubMed] [Google Scholar]
- 74.McLuckie A., Forbes A.M., Ilett K.F. Role of repeated doses of oral activated charcoal in the treatment of acute intoxications. Anaesth Intensive Care. 1990;18:375–384. doi: 10.1177/0310057X9001800315. [DOI] [PubMed] [Google Scholar]
- 75.Pollack M.M., Dunbar B.S., Holbrook P.R., Fields A.I. Aspiration of activated charcoal and gastric contents. Ann Emerg Med. 1981;10:528–529. doi: 10.1016/S0196-0644(81)80009-1. [DOI] [PubMed] [Google Scholar]
- 76.Osterhoudt K.C., Durbin D., Alpern E.R., Henretig F.M. Risk factors for emesis after therapeutic use of activated charcoal in acutely poisoned children. Pediatrics. 2004;113:806–810. doi: 10.1542/peds.113.4.806. [DOI] [PubMed] [Google Scholar]
- 77.Mariani P.J., Pook N. Gastrointestinal tract perforation with charcoal peritoneum complicating orogastric intubation and lavage. Ann Emerg Med. 1993;22:606–609. doi: 10.1016/S0196-0644(05)81954-7. [DOI] [PubMed] [Google Scholar]
- 78.Watson W.A., Cremer K.F., Chapman J.A. Gastrointestinal obstruction associated with multiple-dose activated charcoal. J Emerg Med. 1986;4:401–407. doi: 10.1016/0736-4679(86)90219-2. [DOI] [PubMed] [Google Scholar]
- 79.Menzies D.G., Busuttil A., Prescott L.F. Fatal pulmonary aspiration of oral activated charcoal. BMJ. 1988;297:459–460. doi: 10.1136/bmj.297.6646.459. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Gades N.M., Chyka P.A., Butler A.Y., Virgous C.K., Mandrell T.D. Activated charcoal and the absorption of ferrous sulfate in rats. Vet Hum Toxicol. 2003;45:183–187. [PubMed] [Google Scholar]
- 81.Rangan C., Nordt S.P., Hamilton R., Ingels M., Clark R.F. Treatment of acetaminophen ingestion with a superactivated charcoal-cola mixture. Ann Emerg Med. 2001;37:55–58. doi: 10.1067/mem.2001.111572. [DOI] [PubMed] [Google Scholar]
- 82.Stewart J.J. Effects of emetic and cathartic agents on the gastrointestinal tract and the treatment of toxic ingestion. J Toxicol Clin Toxicol. 1983;20:199–253. doi: 10.3109/15563658308990068. [DOI] [PubMed] [Google Scholar]
- 83.Barceloux D., McGuigan M., Hartigan-Go K. Position statement: Cathartics. J Toxicol Clin Toxicol. 1997;35:743–752. doi: 10.3109/15563659709162570. [DOI] [PubMed] [Google Scholar]
- 84.Smilkstein M.J., Smolinske S.C., Kulig K.W., Rumack B.H. Severe hypermagnesemia due to multiple-dose cathartic therapy. West J Med. 1988;148:208–211. [PMC free article] [PubMed] [Google Scholar]
- 85.Beloosesky Y., Grinblat J., Weiss A., Grosman B., Gafter U., Chagnac A. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med. 2003;163:803–808. doi: 10.1001/archinte.163.7.803. [DOI] [PubMed] [Google Scholar]
- 86.McNamara R.M., Aaron C.K., Gemborys M., Davidheiser S. Sorbitol catharsis does not enhance efficacy of charcoal in a simulated acetaminophen overdose. Ann Emerg Med. 1988;17:243–246. doi: 10.1016/S0196-0644(88)80115-X. [DOI] [PubMed] [Google Scholar]
- 87.al-Shareef A.H., Buss D.C., Allen E.M., Routledge P.A. The effects of charcoal and sorbitol (alone and in combination) on plasma theophylline concentrations after a sustained-release formulation. Hum Exp Toxicol. 1990;9:179–182. doi: 10.1177/096032719000900310. [DOI] [PubMed] [Google Scholar]
- 88.Allerton J.P., Strom J.A. Hypernatremia due to repeated doses of charcoal-sorbitol. Am J Kidney Dis. 1991;17:581–584. doi: 10.1016/s0272-6386(12)80501-4. [DOI] [PubMed] [Google Scholar]
- 89.Martin R.R., Lisehora G.R., Braxton M., Jr, Barcia P.J. Fatal poisoning from sodium phosphate enema. Case report and experimental study. J Am Med Assoc. 1987;257:2190–2192. doi: 10.1001/jama.257.16.2190. [DOI] [PubMed] [Google Scholar]
- 90.Korkis A.M., Miskovitz P.F., Yurt R.W., Klein H. Rectal prolapse after oral cathartics. J Clin Gastroenterol. 1992;14:339–341. doi: 10.1097/00004836-199206000-00014. [DOI] [PubMed] [Google Scholar]
- 91.Ly B.T., Schneir A.B., Clark R.F. Effect of whole bowel irrigation on the pharmacokinetics of an acetaminophen formulation and progression of radiopaque markers through the gastrointestinal tract. Ann Emerg Med. 2004;43:189–195. doi: 10.1016/S0196-0644(03)00720-0. [DOI] [PubMed] [Google Scholar]
- 92.Tenenbein M. Position statement: Whole bowel irrigation. J Toxicol Clin Toxicol. 1997;35:753–762. doi: 10.3109/15563659709001192. [DOI] [PubMed] [Google Scholar]
- 93.Lapatto-Reiniluoto O., Kivisto K.T., Neuvonen P.J. Activated charcoal alone and followed by whole-bowel irrigation in preventing the absorption of sustained-release drugs. Clin Pharmacol Ther. 2001;70:255–260. doi: 10.1067/mcp.2001.118184. [DOI] [PubMed] [Google Scholar]
- 94.Everson G.W., Bertaccini E.J., O’Leary J. Use of whole bowel irrigation in an infant following iron overdose. Am J Emerg Med. 1991;9:366–369. doi: 10.1016/0735-6757(91)90060-W. [DOI] [PubMed] [Google Scholar]
- 95.Smith S.W., Ling L.J., Halstenson C.E. Whole-bowel irrigation as a treatment for acute lithium overdose. Ann Emerg Med. 1991;20:536–539. doi: 10.1016/S0196-0644(05)81610-5. [DOI] [PubMed] [Google Scholar]
- 96.Roberge R.J., Martin T.G. Whole bowel irrigation in an acute oral lead intoxication. Am J Emerg Med. 1992;10:577–583. doi: 10.1016/0735-6757(92)90189-5. [DOI] [PubMed] [Google Scholar]
- 97.Hendrickson R.G., Horowitz B.Z., Norton R.L., Notenboom H. “Parachuting” meth: A novel delivery method for methamphetamine and delayed-onset toxicity from “body stuffing”. Clin Toxicol. 2006;44:379–382. doi: 10.1080/15563650600671746. [DOI] [PubMed] [Google Scholar]
- 98.Scharman E.J., Lembersky R., Krenzelok E.P. Efficiency of whole bowel irrigation with and without metoclopramide pretreatment. Am J Emerg Med. 1994;12:302–305. doi: 10.1016/0735-6757(94)90144-9. [DOI] [PubMed] [Google Scholar]
- 99.Langdon D.E. Colonic perforation with volume laxatives. Am J Gastroenterol. 1996;91:622–623. [PubMed] [Google Scholar]
- 100.Narsinghani U., Chadha M., Farrar H.C., Anand K.S. Life-threatening respiratory failure following accidental infusion of polyethylene glycol electrolyte solution into the lung. J Toxicol Clin Toxicol. 2001;39:105–107. doi: 10.1081/CLT-100102888. [DOI] [PubMed] [Google Scholar]
- 101.Hoffman R.S., Chiang W.K., Howland M.A., Weisman R.S., Goldfrank L.R. Theophylline desorption from activated charcoal caused by whole bowel irrigation solution. J Toxicol Clin Toxicol. 1991;29:191–201. doi: 10.3109/15563659109038611. [DOI] [PubMed] [Google Scholar]
- 102.Ng H.W., Tse M.L., Lau F.L., Chu W. Endoscopic removal of iron bezoar following acute overdose. Clin Toxicol. 2008;46:913–915. doi: 10.1080/15563650701790973. [DOI] [PubMed] [Google Scholar]
- 103.Hojer J., Personne M. Endoscopic removal of slow release clomipramine bezoars in two cases of acute poisoning. Clin Toxicol. 2008;46:317–319. doi: 10.1080/15563650701378738. [DOI] [PubMed] [Google Scholar]
- 104.Wells C.D., Luckritz T.C., Rady M.Y., Zornik J.M., Leighton J.A., Patel B.M. Bezoar formation requiring endoscopic removal after intentional overdose of extended-release nifedipine. Pharmacotherapy. 2006;26:1802–1805. doi: 10.1592/phco.26.12.1802. [DOI] [PubMed] [Google Scholar]
- 105.Choudhary A.M., Taubin H., Gupta T., Roberts I. Endoscopic removal of a cocaine packet from the stomach. J Clin Gastroenterol. 1998;27:155–156. doi: 10.1097/00004836-199809000-00013. [DOI] [PubMed] [Google Scholar]
- 106.Clifton J.C., 2nd, Sigg T., Burda A.M., Leikin J.B., Smith C.J., Sandler R.H. Acute pediatric lead poisoning: Combined whole bowel irrigation, succimer therapy, and endoscopic removal of ingested lead pellets. Pediatr Emerg Care. 2002;18:200–202. doi: 10.1097/00006565-200206000-00013. [DOI] [PubMed] [Google Scholar]
- 107.Foxford R., Goldfrank L. Gastrotomy — A surgical approach to iron overdose. Ann Emerg Med. 1985;14:1223–1226. doi: 10.1016/S0196-0644(85)81034-9. [DOI] [PubMed] [Google Scholar]
- 108.Lapostolle F., Finot M.A., Adnet F., Borron S.W., Baud F.J., Bismuth C. Radiopacity of clomipramine conglomerations and unsuccessful endoscopy: Report of 4 cases. J Toxicol Clin Toxicol. 2000;38:477–482. doi: 10.1081/CLT-100102006. [DOI] [PubMed] [Google Scholar]
- 109.de Prost N., Lefebvre A., Questel F., Roche N., Pourriat J.L., Huchon G., Rabbat A. Prognosis of cocaine body-packers. Intensive Care Med. 2005;31:955–958. doi: 10.1007/s00134-005-2660-y. [DOI] [PubMed] [Google Scholar]
- 110.Schaper A., Hofmann R., Bargain P., Desel H., Ebbecke M., Langer C. Surgical treatment in cocaine body packers and body pushers. Int J Colorectal Dis. 2007;22:1531–1535. doi: 10.1007/s00384-007-0324-9. [DOI] [PubMed] [Google Scholar]
- 111.Bodenham A., Shelly M.P., Park G.R. The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients. Clin Pharmacokinet. 1988;14:347–373. doi: 10.2165/00003088-198814060-00003. [DOI] [PubMed] [Google Scholar]
- 112.Proudfoot A.T., Krenzelok E.P., Vale J.A. Position Paper on urine alkalinization. J Toxicol Clin Toxicol. 2004;42:1–26. doi: 10.1081/CLT-120028740. [DOI] [PubMed] [Google Scholar]
- 113.Jaing T.H., Hung I.J., Chung H.T., Lai C.H., Liu W.M., Chang K.W. Acute hypermagnesemia: A rare complication of antacid administration after bone marrow transplantation. Clin Chim Acta. 2002;326:201–203. doi: 10.1016/S0009-8981(02)00308-X. [DOI] [PubMed] [Google Scholar]
- 114.Scharman E.J. Methods used to decrease lithium absorption or enhance elimination. J Toxicol Clin Toxicol. 1997;35:601–608. doi: 10.3109/15563659709001240. [DOI] [PubMed] [Google Scholar]
- 115.Kleinman G.E., Rodriquez H., Good M.C., Caudle M.R. Hypercalcemic crisis in pregnancy associated with excessive ingestion of calcium carbonate antacid (milk-alkali syndrome): Successful treatment with hemodialysis. Obstet Gynecol. 1991;78:496–499. [PubMed] [Google Scholar]
- 116.Birrer R.B., Shallash A.J., Totten V. Hypermagnesemia-induced fatality following epsom salt gargles. J Emerg Med. 2002;22:185–188. doi: 10.1016/S0736-4679(01)00462-0. [DOI] [PubMed] [Google Scholar]
- 117.Bailey C.S., Weiner J.J., Gibby O.M., Penney M.D. Excessive calcium ingestion leading to milk-alkali syndrome. Ann Clin Biochem. 2008;45:527–529. doi: 10.1258/acb.2008.008006. [DOI] [PubMed] [Google Scholar]
- 118.Chatterjee M., Speiser P.W. Pamidronate treatment of hypercalcemia caused by vitamin D toxicity. J Pediatr Endocrinol Metab. 2007;20:1241–1248. doi: 10.1515/jpem.2007.20.11.1241. [DOI] [PubMed] [Google Scholar]
- 119.Grunfeld J.P., Rossier B.C. Lithium nephrotoxicity revisited. Nat Rev Nephrol. 2009;5:270–276. doi: 10.1038/nrneph.2009.43. [DOI] [PubMed] [Google Scholar]
- 120.Majumdar SR, Kjellstrand CM, Tymchak WJ, Hervas-Malo M, Taylor DA, Teo KK (2009) Forced euvolemic ciuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: A randomized controlled trial. Am J Kidney Dis, in press [DOI] [PubMed]
- 121.Eyer F., Pfab R., Felgenhauer N., Lutz J., Heemann U., Steimer W., Zondler S., Fichtl B., Zilker T. Lithium poisoning: Pharmacokinetics and clearance during different therapeutic measures. J Clin Psychopharmacol. 2006;26:325–330. doi: 10.1097/01.jcp.0000218405.02738.b3. [DOI] [PubMed] [Google Scholar]
- 122.Van Bommel E.F., Kalmeijer M.D., Ponssen H.H. Treatment of life-threatening lithium toxicity with high-volume continuous venovenous hemofiltration. Am J Nephrol. 2000;20:408–411. doi: 10.1159/000013627. [DOI] [PubMed] [Google Scholar]
- 123.Bressolle F., Kinowski J.M., de la Coussaye J.E., Wynn N., Eledjam J.J., Galtier M. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet. 1994;26:457–471. doi: 10.2165/00003088-199426060-00004. [DOI] [PubMed] [Google Scholar]
- 124.Meyer L.M., Miller F.R., Rowen M.J., Bock G., Rutzky J. Treatment of acute leukemia with amethopterin (4-amino, 10-methyl pteroyl glutamic acid) Acta Haematol. 1950;4:157–167. doi: 10.1159/000203749. [DOI] [PubMed] [Google Scholar]
- 125.Goldfarb D.S., Matalon D. Principles and techniques applied to enhance elimination. In: Flomenbaum N.E., Goldfrank L.R., Hoffman R.S., Howland M.A., Lewin N.A., Nelson L.S., editors. Goldfrank’s Toxicologic Emergencies. 8th edn. New York: McGraw-Hill; 2006. pp. 160–72. [Google Scholar]
- 126.Johnson L.Z., Martinez I., Fernandez M.C., Davis C.P., Kasinath B.S. Successful treatment of valproic acid overdose with hemodialysis. Am J Kidney Dis. 1999;33:786–789. doi: 10.1016/S0272-6386(99)70235-0. [DOI] [PubMed] [Google Scholar]
- 127.Lalau J.D., Andrejak M., Moriniere P., Coevoet B., Debussche X., Westeel P.F., Fournier A., Quichaud J. Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol. 1989;27:285–288. [PubMed] [Google Scholar]
- 128.Tapolyai M., Campbell M., Dailey K., Udvari-Nagy S. Hemodialysis is as effective as hemoperfusion for drug removal in carbamazepine poisoning. Nephron. 2002;90:213–215. doi: 10.1159/000049045. [DOI] [PubMed] [Google Scholar]
- 129.Carlsson M., Cortes D., Jepsen S., Kanstrup T. Severe iron intoxication treated with exchange transfusion. Arch Dis Child. 2008;93:321–322. doi: 10.1136/adc.2007.123240. [DOI] [PubMed] [Google Scholar]
- 130.Shannon M., Wernovsky G., Morris C. Exchange transfusion in the treatment of severe theophylline poisoning. Pediatrics. 1992;89:145–147. [PubMed] [Google Scholar]
- 131.Manikian A., Stone S., Hamilton R., Foltin G., Howland M.A., Hoffman R.S. Exchange transfusion in severe infant salicylism. Vet Hum Toxicol. 2002;44:224–227. [PubMed] [Google Scholar]
- 132.Katz B.E., Carver M.W. Acute poisoning with isoniazid treated by exchange transfusion. Pediatrics. 1956;18:72–76. [PubMed] [Google Scholar]
- 133.Sancak R., Kucukoduk S., Tasdemir H.A., Belet N. Exchange transfusion treatment in a newborn with phenobarbital intoxication. Pediatr Emerg Care. 1999;15:268–270. [PubMed] [Google Scholar]
- 134.Kosmidis H.V., Bouhoutsou D.O., Varvoutsi M.C., Papadatos J., Stefanidis C.G., Vlachos P., Scardoutsou A., Kostakis A. Vincristine overdose: Experience with 3 patients. Pediatr Hematol Oncol. 1991;8:171–178. doi: 10.3109/08880019109033445. [DOI] [PubMed] [Google Scholar]
- 135.Coleman M.D., Coleman N.A. Drug-induced methaemoglobinaemia. Treatment issues. Drug Saf. 1996;14:394–405. doi: 10.2165/00002018-199614060-00005. [DOI] [PubMed] [Google Scholar]
- 136.Kwon S.U., Lim S.H., Rhee I., Kim S.W., Kim J.K., Kim D.W., Jeon E.S. Successful whole blood exchange by apheresis in a patient with acute cyclosporine intoxication without long-term sequelae. J Heart Lung Transplant. 2006;25:483–485. doi: 10.1016/j.healun.2005.11.440. [DOI] [PubMed] [Google Scholar]
- 137.Camerino D.C., Desaphy J.F., Tricarico D., Pierno S., Liantonio A. Therapeutic approaches to ion channel diseases. Adv Genet. 2008;64:81–145. doi: 10.1016/S0065-2660(08)00804-3. [DOI] [PubMed] [Google Scholar]
- 138.Diaz-Sylvester P.L., Porta M., Copello J.A. Halothane modulation of skeletal muscle ryanodine receptors: Dependence on Ca2+, Mg2+, and ATP. Am J Physiol Cell Physiol. 2008;294:C1103–1112. doi: 10.1152/ajpcell.90642.2007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 139.Smith F.A., Wittmann C.W., Stern T.A. Medical complications of psychiatric treatment. Crit Care Clin. 2008;24:635–656. doi: 10.1016/j.ccc.2008.05.004. [DOI] [PubMed] [Google Scholar]
- 140.Dunkley E.J., Isbister G.K., Sibbritt D., Dawson A.H., Whyte I.M. The Hunter serotonin toxicity criteria: Simple and accurate diagnostic decision rules for serotonin toxicity. QJM. 2003;96:635–642. doi: 10.1093/qjmed/hcg109. [DOI] [PubMed] [Google Scholar]
- 141.Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991;148:705–713. doi: 10.1176/ajp.148.6.705. [DOI] [PubMed] [Google Scholar]
- 142.Boyer E.W., Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–1120. doi: 10.1056/NEJMra041867. [DOI] [PubMed] [Google Scholar]
- 143.Rusyniak D.E., Sprague J.E. Toxin-induced hyperthermic syndromes. Med Clin North Am. 2005;89:1277–1296. doi: 10.1016/j.mcna.2005.06.002. [DOI] [PubMed] [Google Scholar]
- 144.Ioos V., Das V., Maury E., Baudel J.L., Guechot J., Guidet B., Offenstadt G. A thyrotoxicosis outbreak due to dietary pills in Paris. Ther Clin Risk Manag. 2008;4:1375–1379. doi: 10.2147/tcrm.s4110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 145.Redahan C., Karski J.M. Thyrotoxicosis factitia in a post-aortocoronary bypass patient. Can J Anaesth. 1994;41:969–972. doi: 10.1007/BF03010940. [DOI] [PubMed] [Google Scholar]
- 146.Hsiao A.L., Santucci K.A., Seo-Mayer P., Mariappan M.R., Hodsdon M.E., Banasiak K.J., Baum C.R. Pediatric fatality following ingestion of dinitrophenol: Postmortem identification of a “dietary supplement”. Clin Toxicol. 2005;43:281–285. doi: 10.1081/clt-58946. [DOI] [PubMed] [Google Scholar]
- 147.Argaud L., Ferry T., Le Q.H., Marfisi A., Ciorba D., Achache P., Ducluzeau R., Robert D. Short-and long-term outcomes of heatstroke following the 2003 heat wave in Lyon, France. Arch Intern Med. 2007;167:2177–2183. doi: 10.1001/archinte.167.20.ioi70147. [DOI] [PubMed] [Google Scholar]
- 148.Dematte J.E., O’Mara K., Buescher J., Whitney C.G., Forsythe S., McNamee T., Adiga R.B., Ndukwu I.M. Near-fatal heat stroke during the 1995 heat wave in Chicago. Ann Intern Med. 1998;129:173–181. doi: 10.7326/0003-4819-129-3-199808010-00001. [DOI] [PubMed] [Google Scholar]
- 149.Marzuk P.M., Tardiff K., Leon A.C., Hirsch C.S., Portera L., Iqbal M.I., Nock M.K., Hartwell N. Ambient temperature and mortality from unintentional cocaine overdose. J Am Med Assoc. 1998;279:1795–1800. doi: 10.1001/jama.279.22.1795. [DOI] [PubMed] [Google Scholar]
- 150.Bowyer J.F., Davies D.L., Schmued L., Broening H.W., Newport G.D., Slikker W., Jr, Holson R.R. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther. 1994;268:1571–1580. [PubMed] [Google Scholar]
- 151.Ferris E.B., Blankenhorn M.A., Robinson H.W., Cullen G.E. Heat stroke: Clinical and chemical observations on 44 cases. J Clin Invest. 1938;17:249–262. doi: 10.1172/JCI100949. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 152.Bouchama A., Dehbi M., Chaves-Carballo E. Cooling and hemodynamic management in heatstroke: Practical recommendations. Crit Care. 2007;11:R54. doi: 10.1186/cc5910. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 153.Armstrong L.E., Crago A.E., Adams R., Roberts W.O., Maresh C.M. Whole-body cooling of hyperthermic runners: Comparison of two field therapies. Am J Emerg Med. 1996;14:355–358. doi: 10.1016/S0735-6757(96)90048-0. [DOI] [PubMed] [Google Scholar]
- 154.Costrini A. Emergency treatment of exertional heatstroke and comparison of whole body cooling techniques. Med Sci Sports Exerc. 1990;22:15–18. [PubMed] [Google Scholar]
- 155.Nisijima K., Shioda K., Yoshino T., Takano K., Kato S. Diazepam and chlormethiazole attenuate the development of hyperthermia in an animal model of the serotonin syndrome. Neurochem Int. 2003;43:155–164. doi: 10.1016/S0197-0186(02)00213-9. [DOI] [PubMed] [Google Scholar]
- 156.Derlet R.W., Albertson T.E., Rice P. Antagonism of cocaine, amphetamine, and methamphetamine toxicity. Pharmacol Biochem Behav. 1990;36:745–749. doi: 10.1016/0091-3057(90)90071-O. [DOI] [PubMed] [Google Scholar]
- 157.Laorden M.L., Carrillo E., Miralles F.S., Puig M.M. Effects of diltiazem on hyperthermia induced seizures in the rat pup. Gen Pharmacol. 1990;21:313–315. doi: 10.1016/0306-3623(90)90829-b. [DOI] [PubMed] [Google Scholar]
- 158.Kobayashi S., Bannister M.L., Gangopadhyay J.P., Hamada T., Parness J., Ikemoto N. Dantrolene stabilizes domain interactions within the ryanodine receptor. J Biol Chem. 2005;280:6580–6587. doi: 10.1074/jbc.M408375200. [DOI] [PubMed] [Google Scholar]
- 159.Cherednichenko G., Ward C.W., Feng W., Cabrales E., Michaelson L., Samso M., Lopez J.R., Allen P.D., Pessah I.N. Enhanced excitation-coupled calcium entry in myotubes expressing malignant hyperthermia mutation R163C is attenuated by dantrolene. Mol Pharmacol. 2008;73:1203–1212. doi: 10.1124/mol.107.043299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 160.Reulbach U., Dutsch C., Biermann T., Sperling W., Thuerauf N., Kornhuber J., Bleich S. Managing an effective treatment for neuroleptic malignant syndrome. Crit Care. 2007;11:R4. doi: 10.1186/cc5148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 161.Sakkas P., Davis J.M., Janicak P.G., Wang Z.Y. Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull. 1991;27:381–384. [PubMed] [Google Scholar]
- 162.Massicotte A. Contrast medium-induced nephropathy: Strategies for prevention. Pharmacotherapy. 2008;28:1140–1150. doi: 10.1592/phco.28.9.1140. [DOI] [PubMed] [Google Scholar]
- 163.Rumack B.H. Acetaminophen hepatotoxicity: The first 35 years. J Toxicol Clin Toxicol. 2002;40:3–20. doi: 10.1081/CLT-120002882. [DOI] [PubMed] [Google Scholar]
- 164.Laine J.E., Auriola S., Pasanen M., Juvonen R.O. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica. 2009;39:11–21. doi: 10.1080/00498250802512830. [DOI] [PubMed] [Google Scholar]
- 165.Heard K.J. Acetylcysteine for acetaminophen poisoning. N Engl J Med. 2008;359:285–292. doi: 10.1056/NEJMct0708278. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 166.Lauterburg B.H., Corcoran G.B., Mitchell J.R. Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest. 1983;71:980–991. doi: 10.1172/JCI110853. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 167.Keays R., Harrison P.M., Wendon J.A., Forbes A., Gove C., Alexander G.J., Williams R. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: A prospective controlled trial. BMJ. 1991;303:1026–1029. doi: 10.1136/bmj.303.6809.1026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 168.Harrison P.M., Wendon J.A., Gimson A.E., Alexander G.J., Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991;324:1852–1857. doi: 10.1056/NEJM199106273242604. [DOI] [PubMed] [Google Scholar]
- 169.Devlin J., Ellis A.E., McPeake J., Heaton N., Wendon J.A., Williams R. N-Acetylcysteine improves indocyanine green extraction and oxygen transport during hepatic dysfunction. Crit Care Med. 1997;25:236–242. doi: 10.1097/00003246-199702000-00007. [DOI] [PubMed] [Google Scholar]
- 170.Rank N., Michel C., Haertel C., Lenhart A., Welte M., Meier-Hellmann A., Spies C. N-Acetylcysteine increases liver blood flow and improves liver function in septic shock patients: Results of a prospective, randomized, double-blind study. Crit Care Med. 2000;28:3799–3807. doi: 10.1097/00003246-200012000-00006. [DOI] [PubMed] [Google Scholar]
- 171.Wong B.K., Chan H.C., Corcoran G.B. Selective effects of N-acetylcysteine stereoisomers on hepatic glutathione and plasma sulfate in mice. Toxicol Appl Pharmacol. 1986;86:421–429. doi: 10.1016/0041-008X(86)90369-8. [DOI] [PubMed] [Google Scholar]
- 172.Wong B.K., Galinsky R.E., Corcoran G.B. Dissociation of increased sulfation from sulfate replenishment and hepatoprotection in acetaminophen-poisoned mice by N-acetylcysteine stereoisomers. J Pharm Sci. 1986;75:878–880. doi: 10.1002/jps.2600750910. [DOI] [PubMed] [Google Scholar]
- 173.Tsai C.L., Chang W.T., Weng T.I., Fang C.C., Walson P.D. A patient-tailored N-acetylcysteine protocol for acute acetaminophen intoxication. Clin Ther. 2005;27:336–341. doi: 10.1016/j.clinthera.2005.03.002. [DOI] [PubMed] [Google Scholar]
- 174.Betten D.P., Cantrell F.L., Thomas S.C., Williams S.R., Clark R.F. A prospective evaluation of shortened course oral N-acetylcysteine for the treatment of acute acetaminophen poisoning. Ann Emerg Med. 2007;50:272–279. doi: 10.1016/j.annemergmed.2006.11.010. [DOI] [PubMed] [Google Scholar]
- 175.Daly F.F., Fountain J.S., Murray L., Graudins A., Buckley N.A. Guidelines for the management of paracetamol poisoning in Australia and New Zealand — Explanation and elaboration. Med J Aust. 2008;188:296–301. doi: 10.5694/j.1326-5377.2008.tb01625.x. [DOI] [PubMed] [Google Scholar]
- 176.Smilkstein M.J., Knapp G.L., Kulig K.W., Rumack B.H. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985) N Engl J Med. 1988;319:1557–1562. doi: 10.1056/NEJM198812153192401. [DOI] [PubMed] [Google Scholar]
- 177.Bridger S., Henderson K., Glucksman E., Ellis A.J., Henry J.A., Williams R. Deaths from low dose paracetamol poisoning. BMJ. 1998;316:1724–1725. doi: 10.1136/bmj.316.7146.1724. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 178.Rumack B.H. Acetaminophen misconceptions. Hepatology. 2004;40:10–15. doi: 10.1002/hep.20300. [DOI] [PubMed] [Google Scholar]
- 179.Pakravan N., Waring W.S., Sharma S., Ludlam C., Megson I., Bateman D.N. Risk factors and mechanisms of anaphylactoid reactions to acetylcysteine in acetaminophen overdose. Clin Toxicol. 2008;46:697–702. doi: 10.1080/15563650802245497. [DOI] [PubMed] [Google Scholar]
- 180.Hayes B.D., Klein-Schwartz W., Doyon S. Frequency of medication errors with intravenous acetylcysteine for acetaminophen overdose. Ann Pharmacother. 2008;42:766–770. doi: 10.1345/aph.1K685. [DOI] [PubMed] [Google Scholar]
- 181.Sung L., Simons J.A., Dayneka N.L. Dilution of intravenous N-acetylcysteine as a cause of hyponatremia. Pediatrics. 1997;100:389–391. doi: 10.1542/peds.100.3.389. [DOI] [PubMed] [Google Scholar]
- 182.Yarema M.C., Johnson D.W., Berlin R.J., Sivilotti M.L., Nettel-Aguirre A., Brant R.F., Spyker D.A., Bailey B., Chalut D., Lee J.S., Plint A.C., Purssell R.A., Rutledge T., Seviour C.A., Stiell I.G., Thompson M., Tyberg J., Dart R.C., Rumack B.H. Comparison of the 20-hour intravenous and 72-hour oral acetylcysteine protocols for the treatment of acute acetaminophen poisoning. Ann Emerg Med. 2009;54:606–614. doi: 10.1016/j.annemergmed.2009.05.010. [DOI] [PubMed] [Google Scholar]
- 183.Doyon S., Klein-Schwartz W. Hepatotoxicity despite early administration of intravenous N-acetylcysteine for acute acetaminophen overdose. Acad Emerg Med. 2009;16:34–39. doi: 10.1111/j.1553-2712.2008.00296.x. [DOI] [PubMed] [Google Scholar]
- 184.Smith S.W., Howland M.A., Hoffman R.S., Nelson L.S. Acetaminophen overdose with altered acetaminophen pharmacokinetics and hepatotoxicity associated with premature cessation of intravenous N-acetylcysteine therapy. Ann Pharmacother. 2008;42:1333–1339. doi: 10.1345/aph.1K680. [DOI] [PubMed] [Google Scholar]
- 185.Halcomb S.E., Sivilotti M.L., Goklaney A., Mullins M.E. Pharmacokinetic effects of diphenhydramine or oxycodone in simulated acetaminophen overdose. Acad Emerg Med. 2005;12:169–172. doi: 10.1111/j.1553-2712.2005.tb00859.x. [DOI] [PubMed] [Google Scholar]
- 186.Cetaruk E.W., Dart R.C., Hurlbut K.M., Horowitz R.S., Shih R. Tylenol extended relief overdose. Ann Emerg Med. 1997;30:104–108. doi: 10.1016/S0196-0644(97)70120-3. [DOI] [PubMed] [Google Scholar]
- 187.Fraser T.R. On the characters, actions, and therapeutic uses of the bean of Calabar. Edin Med J. 1863;9:36–56. [Google Scholar]
- 188.Nickalls R.W., Nickalls E.A. The first use of physostigmine in the treatment of atropine poisoning. A translation of Kleinwachter’s paper entitled ‘Observations on the effect of Calabar bean extract as an antidote to atropine poisoning’. Anaesthesia. 1988;43:776–779. doi: 10.1111/j.1365-2044.1988.tb05755.x. [DOI] [PubMed] [Google Scholar]
- 189.Atack J.R., Yu Q.S., Soncrant T.T., Brossi A., Rapoport S.I. Comparative inhibitory effects of various physostigmine analogs against acetyl-and butyrylcholinesterases. J Pharmacol Exp Ther. 1989;249:194–202. [PubMed] [Google Scholar]
- 190.Brossi A., Schonenberger B., Clark O.E., Ray R. Inhibition of acetylcholinesterase from electric eel by (−)-and (+)-physostigmine and related compounds. FEBS Lett. 1986;201:190–192. doi: 10.1016/0014-5793(86)80606-8. [DOI] [PubMed] [Google Scholar]
- 191.Barak D., Ordentlich A., Stein D., Yu Q.S., Greig N.H., Shafferman A. Accommodation of physostigmine and its analogues by acetylcholinesterase is dominated by hydrophobic interactions. Biochem J. 2009;417:213–222. doi: 10.1042/BJ20081276. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 192.Pereira E.F., Hilmas C., Santos M.D., Alkondon M., Maelicke A., Albuquerque E.X. Unconventional ligands and modulators of nicotinic receptors. J Neurobiol. 2002;53:479–500. doi: 10.1002/neu.10146. [DOI] [PubMed] [Google Scholar]
- 193.Pentel P., Peterson C.D. Asystole complicating physostigmine treatment of tricyclic antidepressant overdose. Ann Emerg Med. 1980;9:588–590. doi: 10.1016/S0196-0644(80)80232-0. [DOI] [PubMed] [Google Scholar]
- 194.Suchard J.R. Assessing physostigmine’s contraindication in cyclic antidepressant ingestions. J Emerg Med. 2003;25:185–191. doi: 10.1016/S0736-4679(03)00169-0. [DOI] [PubMed] [Google Scholar]
- 195.Ago J., Ishikawa T., Matsumoto N., Ashequr Rahman M., Kamei C. Mechanism of imipramine-induced seizures in amygdala-kindled rats. Epilepsy Res. 2006;72:1–9. doi: 10.1016/j.eplepsyres.2006.06.022. [DOI] [PubMed] [Google Scholar]
- 196.Fleck C., Braunlich H. Failure of physostigmine in intoxications with tricyclic antidepressants sants in rats. Toxicoloty. 1982;24:334–344. doi: 10.1016/0300-483x(82)90015-4. [DOI] [PubMed] [Google Scholar]
- 197.Burns M.J., Linden C.H., Graudins A., Brown R.M., Fletcher K.E. A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med. 2002;35:374–381. doi: 10.1016/S0196-0644(00)70057-6. [DOI] [PubMed] [Google Scholar]
- 198.Frascogna N. Physostigmine: Is there a role for this antidote in pediatric poisonings? Curr Opin Pediatr. 2007;19:201–205. doi: 10.1097/MOP.0b013e32802c7be1. [DOI] [PubMed] [Google Scholar]
- 199.Claessens Y.E., Cariou A., Monchi M., Soufir L., Azoulay E., Rouges P., Goldgran-Toledano D., Branche F., Dhainaut J.F. Detecting life-threatening lactic acidosis related to nucleosideanalog treatment of human immunodeficiency virus-infected patients, and treatment with l-carnitine. Crit Care Med. 2003;31:1042–1047. doi: 10.1097/01.CCM.0000053649.69377.08. [DOI] [PubMed] [Google Scholar]
- 200.Delaney C.E., Hopkins S.P., Addison C.L. Supplementation with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells. Cancer Lett. 2007;252:195–207. doi: 10.1016/j.canlet.2006.12.027. [DOI] [PubMed] [Google Scholar]
- 201.Lheureux P.E., Penaloza A., Zahir S., Gris M. Science review: Carnitine in the treatment of valproic acid-induced toxicity — What is the evidence? Crit Care. 2005;9:431–440. doi: 10.1186/cc3742. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 202.Katiyar A., Aaron C. Case files of the Children’s Hospital of Michigan Regional Poison Control Center: The use of carnitine for the management of acute valproic acid toxicity. J Med Toxicol. 2007;3:129–138. doi: 10.1007/BF03160923. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 203.Loscher W. Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16:669–694. doi: 10.2165/00023210-200216100-00003. [DOI] [PubMed] [Google Scholar]
- 204.Silva MF, Aires CC, Luis PB, Ruiter JP, Ijlst L, Duran M, Wanders RJ, Tavares de Almeida I (2008) Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review. J Inherit Metab Dis, in press [DOI] [PubMed]
- 205.Ingels M., Beauchamp J., Clark R.F., Williams S.R. Delayed valproic acid toxicity: A retrospective case series. Ann Emerg Med. 2002;39:616–621. doi: 10.1067/mem.2002.124443. [DOI] [PubMed] [Google Scholar]
- 206.Eyer F., Felgenhauer N., Gempel K., Steimer W., Gerbitz K.D., Ziller T. Acute valproate poisoning: Pharmacokinetics, alteration in fatty acid metabolism, and changes during therapy. J Clin Psychopharmacol. 2005;25:376–380. doi: 10.1097/01.jcp.0000168485.76397.5c. [DOI] [PubMed] [Google Scholar]
- 207.Sztajnkrycer M.D. Valproic acid toxicity: Overview and management. J Toxicol Clin Toxicol. 2002;40:789–801. doi: 10.1081/CLT-120014645. [DOI] [PubMed] [Google Scholar]
- 208.Riva R., Albani F., Gobbi G., Santucci M., Baruzzi A. Carnitine disposition before and during valproate therapy in patients with epilepsy. Epilepsia. 1993;34:184–187. doi: 10.1111/j.1528-1157.1993.tb02396.x. [DOI] [PubMed] [Google Scholar]
- 209.Okamura N., Ohnishi S., Shimaoka H., Norikura R., Hasegawa H. Involvement of recognition and interaction of carnitine transporter in the decrease of l-carnitine concentration induced by pivaic acid and valproic acid. Pharm Res. 2006;23:1729–1735. doi: 10.1007/s11095-006-9002-9. [DOI] [PubMed] [Google Scholar]
- 210.Spahr L., Negro F., Rubbia-Brandt L., Marinescu O., Goodman K., Jordan M., Frossard J.L., Hadengue A. Acute valproate-associated microvesicular steatosis: Could the [13C]methionine breath test be useful to assess liver mitochondrial function? Dig Dis Sci. 2001;46:2758–2761. doi: 10.1023/A:1012791832730. [DOI] [PubMed] [Google Scholar]
- 211.Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr. 2007;19:206–210. doi: 10.1097/MOP.0b013e32805e879a. [DOI] [PubMed] [Google Scholar]
- 212.De Vivo D.C., Bohan T.P., Coulter D.L., Dreifuss F.E., Greenwood R.S., Nordli D.R., Jr, Shields W.D., Stafstrom C.E., Tein I. l-carnitine supplementation in childhood epilepsy: Current perspectives. Epilepsia. 1998;39:1216–1225. doi: 10.1111/j.1528-1157.1998.tb01315.x. [DOI] [PubMed] [Google Scholar]
- 213.Anil M., Helvaci M., Ozbal E., Kalenderer O., Anil A.B., Dilek M. Serum and muscle carnitine levels in epileptic children receiving sodium valproate. J Clin Neurol. 2009;24:80–86. doi: 10.1177/0883073808321060. [DOI] [PubMed] [Google Scholar]
- 214.Zelnik N., Isler N., Goez H., Shiffer M., David M., Shahar E. Vigabatrin, lamotrigine, tipiramate and serum carnitine levels. Pediatr Neurol. 2008;39:18–21. doi: 10.1016/j.pediatrneurol.2008.03.005. [DOI] [PubMed] [Google Scholar]
- 215.Verrotti A., Greco R., Morgese G., Chiarelli F. Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs. Int J Clin Lab Res. 1999;29:36–40. doi: 10.1007/s005990050060. [DOI] [PubMed] [Google Scholar]
- 216.Bahles H., Sewell A.C., Wenzel D. The effect of carnitine supplementation in valproate-induced hyperammonaemia. Acta Paediatr. 1996;85:446–449. doi: 10.1111/j.1651-2227.1996.tb14058.x. [DOI] [PubMed] [Google Scholar]
- 217.Gidal B.E., Inglese C.M., Meyer J.F., Antonopolous J., Rust R.S. Diet-and valproate-induced transient hyperammonemia: Effect of l-carnitine. Pediatr Neurol. 1997;16:301–305. doi: 10.1016/S0887-8994(97)00026-X. [DOI] [PubMed] [Google Scholar]
- 218.Van Wouwe J.P. Carnitine deficienty during valproic acid treatment. IntJ Vitam Nutr Res. 1995;65:211–214. [PubMed] [Google Scholar]
- 219.Ishikura H., Matsuo N., Matsubara M., Ishibara T., Takeyama N., Tanaka T. valproic acid overdose and l-carnitine therapy. J Anal Toxicol. 1996;20:55–58. doi: 10.1093/jat/20.1.55. [DOI] [PubMed] [Google Scholar]
- 220.Romero-Falcon A., de la Santa-Belda E., Garci-Contreras R., Varela J.M. A case of valproate-associated hepatotoxicity treated with l-carnitine. Eur J Intern Med. 2003;14:338–340. doi: 10.1016/S0953-6205(03)00104-3. [DOI] [PubMed] [Google Scholar]
- 221.Wadzinski J., Franks R., Roane D., Bayard M. Valproate-associated hyperammonemic encephalopathy. J Am Broad Fam Med. 2007;20:499–502. doi: 10.3122/jabfm.2007.05.070062. [DOI] [PubMed] [Google Scholar]
- 222.Bohan T.P., Helton E., McDonald I., Konig S., Gazitt S., Sugimoto T., Scheffner D., Cusmano L., Li S., Koch G. Effect of l-carnitine treatment for valproate-inducedhepatotoxicity. Neurology. 2001;56:1405–1409. doi: 10.1212/wnl.56.10.1405. [DOI] [PubMed] [Google Scholar]
- 223.Raskind J.Y., El-Chaar G.M. The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother. 2000;34:630–638. doi: 10.1345/aph.19242. [DOI] [PubMed] [Google Scholar]
- 224.Beauchamp J., Olson K. Valproic acid overdoses: A retrospective study comparing serum drug levels and the incidence of adverse outcomes. J Toxicol Clin Toxicol. 1999;37:637–638. [Google Scholar]
- 225.LoVecchio F., Shriki L., Samaddar R. l-carnitine was safely administered in the setting of valproate toxicity. Am J Emerg Med. 2005;23:321–322. doi: 10.1016/j.ajem.2005.02.015. [DOI] [PubMed] [Google Scholar]
- 226.Sigma-Tau Pharmaceuticals Inc . CARNITOR®) Tablets (330 mg). CARNITOR® (levocarnitine) Oral Solution (1 g per 10 mL multidose). CARNITOR® SF (levocarnitine) Surgar-Free Oral Solution (1 g per 10 ml multidose) Gaithersburg, MD: Sigma-Tau Pharmaceuticals Inc.; 2006. [Google Scholar]
- 227.Jung J., Eo E., Ahn K.O. A case of hemoperfusion of l-carnitine management in valproic acid overdose. Am J Emerg Med. 2008;26:388. doi: 10.1016/j.ajem.2007.07.032. [DOI] [PubMed] [Google Scholar]
- 228.Rossini P.M., Marchionno L., Gambi D., Pirchio M., Del Rosso G., Albertazzi A. EMG changes in chronically dialyzed uraemic subjects undergoing d,l-carnitine treatment. Ital J Neurol Sci. 1981;2:255–262. doi: 10.1007/BF02335405. [DOI] [PubMed] [Google Scholar]
- 229.Tsoko M., Beauseigneur F., Gresti J., Niot I., Damarquoy J., Biochot J., Bezard J., Rochette L., Clouet P. Enhancement of activities relative to fatty acid oxidation in the liver of rats depleted of l-carnitine by d-carnitine and a γ-butyrobetaine hydroxylase inhibitor. Biochem Pharmacol. 1995;49:1403–1410. doi: 10.1016/0006-2952(95)00019-V. [DOI] [PubMed] [Google Scholar]
- 230.Seltzer H.S. Drug-induced hypoglycemia. A review of 1418 cases. Endocrinol Metab Clin North Am. 1989;18:163–183. [PubMed] [Google Scholar]
- 231.Chan J.C., Cockram C.S., Critchley J.A. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf. 1996;15:135–157. doi: 10.2165/00002018-199615020-00005. [DOI] [PubMed] [Google Scholar]
- 232.Wender R., Brown A.M., Fern R., Swanson R.A., Farrell K., Ransom B.R. Astrocytic glycogen influences axon function and survival during glucose deprivation in central white matter. J Neurosci. 2000;20:6804–6810. doi: 10.1523/JNEUROSCI.20-18-06804.2000. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 233.Boyle P.J., Kempers S.F., O’Connor A.M., Nagy R.J. Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:1726–1731. doi: 10.1056/NEJM199512283332602. [DOI] [PubMed] [Google Scholar]
- 234.Dalan R., Leow M.K., George J., Chian K.Y., Tan A., Han H.W., Cheow S.P. Neuroglycopenia and adrenergic responses to hypoglycaemia: Insights from a local epidemic of serendipitous massive overdose of glibenclamide. Diabet Med. 2009;26:105–109. doi: 10.1111/j.1464-5491.2008.02634.x. [DOI] [PubMed] [Google Scholar]
- 235.Kuzak N., Brubacher J.R., Kennedy J.P. Reversal of salicylate-induced euglycemic delirium with dextrose. Clin Toxicol (Phila) 2007;45:526–529. doi: 10.1080/15563650701365800. [DOI] [PubMed] [Google Scholar]
- 236.Abdelmalik P.A., Shannon P., Yiu A., Liang P., Adamchik Y., Weisspapir M., Samoilova M., Burnham W.M., Carlen P.L. Hypoglycemic seizures during transient hypoglycemia exacerbate hippocampal dysfunction. Neurobiol Dis. 2007;26:646–660. doi: 10.1016/j.nbd.2007.03.002. [DOI] [PubMed] [Google Scholar]
- 237.Auer R.N., Wieloch T., Olsson Y., Siesjo B.K. The distribution of hypoglycemic brain damage. Acta Neuropathol. 1984;64:177–191. doi: 10.1007/BF00688108. [DOI] [PubMed] [Google Scholar]
- 238.Hospira, Inc. Concentrated Dextrose for Intravenous Administration. Lake Forest, IL: Hospira Inc.; 2004. [Google Scholar]
- 239.Cunningham P., Afzal-Ahmed I., Naftalin R.J. Docking studies show that d-glucose and quercetin slide through the transporter GLUT1. J Biol Chem. 2006;281:5797–5803. doi: 10.1074/jbc.M509422200. [DOI] [PubMed] [Google Scholar]
- 240.Yosowitz P., Ekland D.A., Shaw R.C., Parsons R.W. Peripheral intravenous infiltration necrosis. Ann Surg. 1975;182:553–556. doi: 10.1097/00000658-197511000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 241.MaLeod D.B., Montoya D.R., Fick G.H., Jessen K.R. The effect of 25 grams i.v. glucose on serum inorganic phosphate levels. Ann Emerg Med. 1994;23:524–528. doi: 10.1016/S0196-0644(94)70072-9. [DOI] [PubMed] [Google Scholar]
- 242.Novartis Pharma Stein AG . Sandostain® octreotide acetate Injection Prescribing Information. Stein, Switzerland: Novartis Pharma Stein AG; 2008. [Google Scholar]
- 243.Doyle M.E., Egan J.M. Pharmacological agents that directly modulate insulin secretion. Pharmacol Rev. 2003;55:105–131. doi: 10.1124/pr.55.1.7. [DOI] [PubMed] [Google Scholar]
- 244.Gerich J.E. Oral hypoglycemic agents. N Engl J Med. 1989;321:1231–1245. doi: 10.1056/NEJM198911023211805. [DOI] [PubMed] [Google Scholar]
- 245.Hansen J.B., Arkhammar P.O., Bodvarsdottir T.B., Wahl P. Inhibition of insulin secretion as a new drug target in the treatment of metabolic disorders. Curr Med Chem. 2004;11:1595–1615. doi: 10.2174/0929867043365026. [DOI] [PubMed] [Google Scholar]
- 246.Lahlou H., Guillermet J., Hortala M., Vernejoul F., Pyronnet S., Bousquet C., Susini C. Molecular signaling of somatostatin receptors. Ann NY Acad Sci. 2004;1014:121–131. doi: 10.1196/annals.1294.012. [DOI] [PubMed] [Google Scholar]
- 247.Di Mauro M., Papalia G., Le Moli R., Nativo B., Nocoletti F., Lunetta M. Effect of octreotide on insulin requirement, hepatic glucose production, growth hormone, glucagon and c-peptide levels in type 2 diabetic patients with chronic renal failure or normal renal function. Diabetes Res Clin Pract. 2001;51:45–50. doi: 10.1016/S0168-8227(00)00203-5. [DOI] [PubMed] [Google Scholar]
- 248.Mordel A., Sivilotti M.L.A., Old A.C., Ferm R.P. Octroetide for pediatric sulfonylurea poisoning. Toxicol Clin Toxicol. 1998;36:437. [Google Scholar]
- 249.Skugor M., Siraj E.S. A diabetic woman with worsening heart failure, hunger, and tremor. Cleve Clin J Med. 2003;70:882–888. doi: 10.3949/ccjm.70.10.882. [DOI] [PubMed] [Google Scholar]
- 250.Green R.S., Palatnick W. Effectiveness of octreotide in a case of refractory sulfonylurea-induced hypoglycemia. J Emerg Med. 2003;25:283–287. doi: 10.1016/S0736-4679(03)00204-X. [DOI] [PubMed] [Google Scholar]
- 251.Boyle P.J., Justice K., Krentz A.J., Nagy R.J., Schade D.S. Octreotide reverses hyperinsulinemia and prevents hypoglycemia induced by sulfonylurea overdoses. J Clin Endocrinol Metab. 1993;76:752–756. doi: 10.1210/jc.76.3.752. [DOI] [PubMed] [Google Scholar]
- 252.McLaughlin S.A., Crandall C.S., McKinney P.E. Octreotide: An antidote for sulfonylurea-induced hypoglycemia. Ann Emerg Med. 2000;36:133–138. doi: 10.1067/mem.2000.108183. [DOI] [PubMed] [Google Scholar]
- 253.Fasano C.J., O’Malley G., Dominici P., Aguilera E., Latta D.R. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. Ann Emerg Med. 2008;51:400–406. doi: 10.1016/j.annemergmed.2007.06.493. [DOI] [PubMed] [Google Scholar]
- 254.Gul M., Carder B., Girisgin S., Ayan M., Kocak S., Unlu A. The effectiveness of various doses of octreotide for sulfonylurea-induced hypoglycemia after overdose. Adv Ther. 2006;23:878–884. doi: 10.1007/BF02850209. [DOI] [PubMed] [Google Scholar]
- 255.Fleseriu M., Skugor M., Chinnappa P., Siraj E.S. Successful treatment of sulfonylurea-induced prolonged hypoglycemia with use of octreotide. Endocr Pract. 2006;12:635–640. doi: 10.4158/EP.12.6.635. [DOI] [PubMed] [Google Scholar]
- 256.Carr R., Zed P.J. Octreotide for sulfonylurea-induced hypoglycemia following overdose. Ann Pharmacother. 2002;36:1727–1732. doi: 10.1345/aph.1C076. [DOI] [PubMed] [Google Scholar]
- 257.Tenenbein M.S., Tenenbein M. Anaphylactoid reaction to octreotide. Clin Toxicol. 2006;44:707. [Google Scholar]
- 258.Calello D.P., Kelly A., Osterhoudt K.C. Case files of the Medical Toxicology Fellowship Training Program at the Children’s Hospital of Philadelphia: A pediatric exploratory sulfonylurea ingestion. J Med Toxicol. 2006;2:19–24. doi: 10.1007/BF03161009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 259.Curtis J.A., Greenberg M.I. Bradycardia and hyperkalemia associated with octreotide administration. Clin Toxicol. 2006;44:498. [Google Scholar]
- 260.Rath S., Bar-Zeev N., Anderson K., Fahy R., Roseby R. Octreotide in children with hypoglycaemia due of sulfonylurea ingestion. J Paediatr Child Health. 2008;44:383–384. doi: 10.1111/j.1440-1754.2008.01339.x. [DOI] [PubMed] [Google Scholar]
- 261.Al-Shanafey S., Habib Z., AlNassar S. Laparoscopic pancreatectomy for persistent hyperinsulinemic hypoglycemia of infancy. J Pediatr Surg. 2009;44:134–138. doi: 10.1016/j.jpedsurg.2008.10.120. [DOI] [PubMed] [Google Scholar]
- 262.Ferraz D.P., Almeida M.A., Mello B.F. Octreotide therapy for persistent hyperinsulinemic hypoglycemia of infancy. Arq Bras Endocrinol Metabol. 2005;49:460–467. doi: 10.1590/s0004-27302005000300020. [DOI] [PubMed] [Google Scholar]
- 263.Phillips R.E., Warrell D.A., Looareesuwan S., Turner R.C., Bloom S.R., Quantrill D., Moore A.R. Effectiveness of SMS 201–995, a synthetic, long-acting somatostatin analogue, in treatment of quinine-induced hyperinsulinaemia. Lancet. 1986;1:713–716. doi: 10.1016/S0140-6736(86)91103-7. [DOI] [PubMed] [Google Scholar]
- 264.Phillips R.E., Looareesuvan S., Molyneux M.E., Hatz C., Warrell D.A. Hypoglycaemia and counterregulatory hormone responses in severe falciparum malaria: Treatment with sandostatin. Q J Med. 1993;86:233–240. [PubMed] [Google Scholar]
- 265.Lheureux P.E., Zahir S., Penaloza A., Gris M. Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide. Crit Care. 2005;9:543–549. doi: 10.1186/cc3807. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 266.Harris A.G. Somatostatin and somatostaiin analogues: Pharmacokinetics and pharmacodynamic effects. Gut. 1994;35:1–4. doi: 10.1136/gut.35.3_Suppl.S1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 267.Kalman S.D., Rogers R., Barrueto F., Jr Glyburide sold as “Street Steroid” causes hypoglycemia complicated by inappro priate IV administration of octreotide. Clin Toxicol. 2006;44:713–714. [Google Scholar]
- 268.Lamberts S.W., van der Lely A.J., de Herder W.W., Hofland L.J. Octreotide. N Engl J Med. 1996;334:246–254. doi: 10.1056/NEJM199601253340408. [DOI] [PubMed] [Google Scholar]
- 269.Mohnike K., Blankenstein O., Pfuetzner A., Potzsch S., Schober E., Steiner S., Hardy O.T., Grimberg A., van Waarde W.M. Long-term non-surgical therapy of severe persistent congenital hyperinsulinism with glucagon. Horm Res. 2008;70:59–64. doi: 10.1159/000129680. [DOI] [PubMed] [Google Scholar]
- 270.Garibaldi R.A., Drusin R.E., Ferebee S.H., Gregg M.B. Isoniazid-associated hepatitis. Report of an outbreak. Am Rev Respir Dis. 1972;106:357–365. doi: 10.1164/arrd.1972.106.3.357. [DOI] [PubMed] [Google Scholar]
- 271.Peloquin C.A. therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62:2169–2183. doi: 10.2165/00003495-200262150-00001. [DOI] [PubMed] [Google Scholar]
- 272.Lheureux P., Penaloza A., Gris M. Pyridoxine in clinical toxicology: A review. Eur J Emerg Med. 2005;12:78–85. doi: 10.1097/00063110-200504000-00007. [DOI] [PubMed] [Google Scholar]
- 273.Sullivan E.A., Geoffroy P., Weisman R., Hoffman R., Frieden T.R. Isoniazid poisonings in New York City. J Emerg Med. 1998;16:57–59. doi: 10.1016/S0736-4679(97)00242-4. [DOI] [PubMed] [Google Scholar]
- 274.Brown C.V. Acute isoniazid poisoning. Am Rev Respir Dis. 1972;105:206–216. doi: 10.1164/arrd.1972.105.2.206. [DOI] [PubMed] [Google Scholar]
- 275.Agrawal R.L., Dwivedi N.C., Agrawal M., Jain S., Agrawal A. Accidental isoniazid poisoning — A report. Indian J Tuberc. 2008;55:94–96. [PubMed] [Google Scholar]
- 276.Handbook of Anti-Tuberculosis Agents Isoniazid. Tuberculosis. 2008;88:112–116. doi: 10.1016/S1472-9792(08)70011-8. [DOI] [PubMed] [Google Scholar]
- 277.Dunlop D.S., Neidle A. The origin and turnover of d-serine in brain. Biochem Biophys Res Commun. 1997;235:26–30. doi: 10.1006/bbrc.1997.6724. [DOI] [PubMed] [Google Scholar]
- 278.Mustafa A.K., van Rossum D.B., Patterson R.L., Maag D., Ehmsen J.T., Gazi S.K., Chakraborty A., Barrow R.K., Amzel L.M., Snyder S.H. Glutamatergic regulation of serine recemase via reversal of PIP2 inhibition. Proc Natl Acad Sci USA. 2009;106:2921–2926. doi: 10.1073/pnas.0813105106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 279.Wood J.D., Peesker S.J. The effect on GABA metabolism in brain of isonicotinic acid hydrazide and pyridoxine as a fuction of time after administration. J Neurochem. 1972;19:1527–1537. doi: 10.1111/j.1471-4159.1972.tb05097.x. [DOI] [PubMed] [Google Scholar]
- 280.Hankins D.G., Saxena K., Faville R.J., Jr, Warren B.J. Profound acidosis caused by isoniazid ingestion. Am J Emerg Med. 1987;5:165–166. doi: 10.1016/0735-6757(87)90098-2. [DOI] [PubMed] [Google Scholar]
- 281.Chin L., Sievers M.L., Herrier R.N., Picchioni A.L. Convulsions as the etiology of lactic acidosis in acute isoniazid toxicity in dogs. Toxicol Appl Pharmacol. 1979;49:377–384. doi: 10.1016/0041-008X(79)90263-1. [DOI] [PubMed] [Google Scholar]
- 282.Wason S., Lacouture P.G., Lovejoy F.H., Jr Single high-dose pyridoxine treatment for isoniazid overdose. J Am Med Assoc. 1981;246:1102–1104. doi: 10.1001/jama.246.10.1102. [DOI] [PubMed] [Google Scholar]
- 283.Terman D.S., Teitelbaum D.T. Isoniazid self-poisoning. Neurology. 1970;20:299–304. doi: 10.1212/wnl.20.3.299. [DOI] [PubMed] [Google Scholar]
- 284.Jen M, Shah KN, Yan AC (2008) Cutaneous changes in nutritional disease. In: K Wolff, LA Goldsmith, SI Katz, BA Gilchrest, AS Paller, DJ Leffell (eds). Fitzpatrick’s Dermatology in General Medicine, 7th edn., The McGraw-Hill Companies Inc. (http://www.accessmedicine. com/content.aspx?aID=2964061, accessed April 6, 2009)
- 285.Miller J., Robinson A., Percy A.K. Acute isoniazid poisoning in childhood. Am J Dis Child. 1980;134:290–292. doi: 10.1001/archpedi.1980.02130150044011. [DOI] [PubMed] [Google Scholar]
- 286.Brent J., Vo N., Kulig K., Rumack B.H. Reversal of prolonged isoniazid-induced coma by pyridoxine. Arch Intern Med. 1990;150:1751–1753. doi: 10.1001/archinte.150.8.1751. [DOI] [PubMed] [Google Scholar]
- 287.Shah B.R., Santucci K., Sinert R., Steiner P. Acute isoniazid neurotoxicity in an urban hospital. Pediatrics. 1995;95:700–704. [PubMed] [Google Scholar]
- 288.Alvarez F.G., Guntupalli K.K. Isoniazid overdose: Four case reports and review of the literature. Intensive Care Med. 1995;21:641–644. doi: 10.1007/BF01711541. [DOI] [PubMed] [Google Scholar]
- 289.Chin L., Sievers M.L., Laird H.E., Herrier R.N., Picchioni A.L. Evaluation of diazepam and pyridoxine as antidotes to isoniazid intoxication in rats and dogs. Toxicol Appl Pharmacol. 1978;45:713–722. doi: 10.1016/0041-008X(78)90164-3. [DOI] [PubMed] [Google Scholar]
- 290.Morrow L.E., Wear R.E., Schuller D., Malesker M. Acute isoniazid toxicity and the need for adequate pyridoxine supplies. Pharmacotherapy. 2006;26:1529–1532. doi: 10.1592/phco.26.10.1529. [DOI] [PubMed] [Google Scholar]
- 291.Scharman E.J., Rosencrane J.G. Isoniazid toxicity: A survey of pyridoxine availability. Am J Emerg Med. 1994;12:386–388. doi: 10.1016/0735-6757(94)90178-3. [DOI] [PubMed] [Google Scholar]
- 292.Schaumburg H., Kaplan J., Windebank A., Vick N., Rasmus S., Pleasure D., Brown M.J. Sensory neuropathy from pyridoxine abuse. A new megavitamin syndrome. N Engl J Med. 1983;309:445–448. doi: 10.1056/NEJM198308253090801. [DOI] [PubMed] [Google Scholar]
- 293.Bredemann J.A., Krechel S.W., Eggers G.W., Jr Treatment of refractory seizures in massive isoniazid overdose. Anesth Analg. 1990;71:554–557. doi: 10.1213/00000539-199011000-00018. [DOI] [PubMed] [Google Scholar]
- 294.Hensley M.L., Hagerty K.L., Kewalramani T., Green D.M., Meropol N.J., Wasserman T.H., Cohen G.I., Emami B., Gradishar W.J., Mitchell R.B., Thigpen J.T., Trotti A., 3rd, von Hoff D., Schuchter L.M. American Society of Clinical Oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol. 2009;27:127–145. doi: 10.1200/JCO.2008.17.2627. [DOI] [PubMed] [Google Scholar]
- 295.Cetingul N., Midyat L., Kantar M., Demirag B., Aksoylar S., Kansoy S. Cytoprotective effects of amifostine in the treatment of childhood malignancies. Pediatr Blood Cancer. 2009;52:829–833. doi: 10.1002/pbc.21959. [DOI] [PubMed] [Google Scholar]
- 296.Batista C.K., Mota J.M., Souza M.L., Leitao B.T., Souza M.H., Brito G.A., Cunha F.Q., Ribeiro R.A. Amifostine and glutathione preven ifosfamide-and acrolein-induced hemorrhagic cystitis. Cancer Chemother Pharmacol. 2007;59:71–77. doi: 10.1007/s00280-006-0248-z. [DOI] [PubMed] [Google Scholar]
- 297.Gandara D.R., Nahhas W.A., Adelson M.D., Lichtman S.M., Podczaski E.S., Yanovich S., Homesley H.D., Braly P., Ritch P.S., Weisberg S.R. Randomized placebo-controlled multicenter evaluation of diethyldithiocarbamate for chemoprotection against cisplatin-induced toxicities. J Clin Oncol. 1995;13:490–496. doi: 10.1200/JCO.1995.13.2.490. [DOI] [PubMed] [Google Scholar]
- 298.Crawford J., Armitage J., Balducci L., Bennett C., Blayney D.W., Cataland S.R., Dale D.C., Demetri G.D., Erba H.P., Foran J., Freifeld A.G., Goemann M., Heaney M.L., Htoy S., Hudock S., Kloth D.D., Kuter D.J., Lyman G.H., Michaud L.B., Miyata S.C., Tallman M.S., Vadhan-Raj S., Westervelt P., Wong M.K. Myeloid growth factors. J Natl Compr Canc Netw. 2009;7:64–83. doi: 10.6004/jnccn.2009.0006. [DOI] [PubMed] [Google Scholar]
- 299.Wyeth Pharmaceuticals Inc . NEUMEGA® [nu-meg<a] (oprelvekin) Philadelphia, PA: Wyeth Pharmaceuticals Inc.; 2009. [Google Scholar]
- 300.Wengstrom Y., Margulies A. European Oncology Nursing Society extravasation guidelines. Eur J Oncol Nurs. 2008;12:357–361. doi: 10.1016/j.ejon.2008.07.003. [DOI] [PubMed] [Google Scholar]
- 301.TopoTarget USA Inc (2007) Totect™ (Dexrazoxane) for injection. Totect™ Package Insert. Distributed by Integrated Commercialization Solutions. Manufactured by Ben Venue Laboratories Inc., and Hameln Pharmaceuticals GmbH for TopoTarget A/S. Marketed by TopoTarget USA Inc., Rockaway, NJ
- 302.Mouridsen H.T., Langer S.W., Buter J., Eidtmann H., Rosti G., de Wit M., Knoblauch P., Rasmussen A., Dahlstrom K., Jensen P.B., Giaccone G. Treatment of anthracycline extravasation with Savene (dexrazoxane): Results from two prospective clinical multicentre studies. Ann Oncol. 2007;18:546–550. doi: 10.1093/annonc/mdl413. [DOI] [PubMed] [Google Scholar]
- 303.Frost A., Gmehling D., Azemar M., Unger C., Mross K. Treatment of anthracycline extravasation with dexrazoxane — Clinical experience. Onkologie. 2006;29:314–318. doi: 10.1159/000093480. [DOI] [PubMed] [Google Scholar]
- 304.Kane R.C., McGuinn W.D., Jr, Dagher R., Justice R., Pazdur R. Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. Oncologist. 2008;13:445–450. doi: 10.1634/theoncologist.2007-0247. [DOI] [PubMed] [Google Scholar]
- 305.Reeves D. Management of anthracycline extravasation injuries. Ann Pharmacother. 2007;41:1238–1242. doi: 10.1345/aph.1H700. [DOI] [PubMed] [Google Scholar]
- 306.Yan T, Deng S, Metzger A, Godtel-Armbrust U, Porter AC, Wojnowski L (2009) Topoisomerase IIα-dependent and_-independent apoptotic effects of dexrazoxane and doxorubicin. Mol Cancer Ther, in press [DOI] [PubMed]
- 307.Dexrazoxane New indication. Anthracycline extravasation Continue using dimethyl sulfoxide Prescrire Int. 2009;18:6–8. [PubMed] [Google Scholar]
- 308.Sacks M.S., Bradford G.T., Schoenbach E.B. The response of acute leukemia to the administration of the folic acid antagonists, aminopterin and a-methopterin; Report of 14 cases. Ann Intern Med. 1950;32:80–115. doi: 10.7326/0003-4819-32-1-80. [DOI] [PubMed] [Google Scholar]
- 309.Li M.C., Hertz R., Spencer D.B. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med. 1956;93:361–366. doi: 10.3181/00379727-93-22757. [DOI] [PubMed] [Google Scholar]
- 310.Abel E.A. Immunosuppressant and cytotoxic drugs: Unapproved uses or indications. Clin Dermatol. 2000;18:95–101. doi: 10.1016/S0738-081X(99)00098-X. [DOI] [PubMed] [Google Scholar]
- 311.Roenigk H.H., Jr, Auerbach R., Maibach H., Weinstein G., Lebwohl M. Methotrexate in psoriasis: Consensus conference. J Am Acad Dermatol. 1998;38:478–485. doi: 10.1016/S0190-9622(98)70508-0. [DOI] [PubMed] [Google Scholar]
- 312.Borchers A.T., Keen C.L., Cheema G.S., Gershwin M.E. The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum. 2004;34:465–483. doi: 10.1016/j.semarthrit.2003.12.003. [DOI] [PubMed] [Google Scholar]
- 313.Buchen S., Ngampolo D., Melton R.G., Hasan C., Zoubek A., Henze G., Bode U., Fleischhack G. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer. 2005;92:480–487. doi: 10.1038/sj.bjc.6602337. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 314.Moisa A., Fritz P., Benz D., Wehner H.D. Iatrogenically-related, fatal methotrexate intoxication: A series of four cases. Forensic Sci Int. 2006;156:154–157. doi: 10.1016/j.forsciint.2004.12.031. [DOI] [PubMed] [Google Scholar]
- 315.Widemann B.C., Balis F.M., Kempf-Bielack B., Bielack S., Pratt C.B., Ferrari S., Bacci G., Craft A.W., Adamson P.C. High-dos methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004;100:2222–2232. doi: 10.1002/cncr.20255. [DOI] [PubMed] [Google Scholar]
- 316.Dervieux T., Furst D., Lein D.O., Capps R., Smith K., Walsh M., Kremer J. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, amin oimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50:2766–2774. doi: 10.1002/art.20460. [DOI] [PubMed] [Google Scholar]
- 317.Genestier L., Paillot R., Quemeneur L., Izeradjene K., Revillard J.P. Mechanisms of action of methotrexate. Immunopharmacology. 2000;47:247–257. doi: 10.1016/S0162-3109(00)00189-2. [DOI] [PubMed] [Google Scholar]
- 318.Sasaki K., Tanaka J., Fujimoto T. Theoretically required urinary flow during high-dose methotrexate infusion. Cancer Chemother Pharmacol. 1984;13:9–13. doi: 10.1007/BF00401438. [DOI] [PubMed] [Google Scholar]
- 319.Bleyer W.A. Methotrexate: Clinical pharmacology, current status and therapeutic guidelines. Cancer Treat Rev. 1977;4:87–101. doi: 10.1016/S0305-7372(77)80007-8. [DOI] [PubMed] [Google Scholar]
- 320.Nirenberg A., Mosende C., Mehta B.M., Gisolfi A.L., Rosen G. High-dose methotrexate with citrovorum factor rescue: Predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treat Rep. 1977;61:779–783. [PubMed] [Google Scholar]
- 321.Flombaum C.D., Meyers P.A. High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol. 1999;17:1589–1594. doi: 10.1200/JCO.1999.17.5.1589. [DOI] [PubMed] [Google Scholar]
- 322.Chabner B.A., Young R.C. Threshold methotrexate concentration for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest. 1973;52:1804–1811. doi: 10.1172/JCI107362. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 323.Schilsky R.L., Ratain M.J. Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J natl Cancer Inst. 1990;82:1411–1415. doi: 10.1093/jnci/82.17.1411. [DOI] [PubMed] [Google Scholar]
- 324.Goorin A., Strother D., Poplack D., Letvak L.A., George M., Link M. Safety and efficacy of l-leucovorin rescue following high-dose methotrexate for osteosarcoma. Med Pediatr Oncol. 1995;24:362–367. doi: 10.1002/mpo.2950240605. [DOI] [PubMed] [Google Scholar]
- 325.Jardine L.F., Ingram L.C., Bleyer W.A. Intrathecal leucovorin after intrathecal methotrexate overdose. J Pediatr Hematol Oncol. 1996;18:302–304. doi: 10.1097/00043426-199608000-00014. [DOI] [PubMed] [Google Scholar]
- 326.Krause A.S., Weihrauch M.R., Bode U., Fleischhack G., Elter T., Heuer T., Engert A., Diehl V., Josting A. Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy. Leuk Lymphoma. 2002;43:2139–2143. doi: 10.1080/1042819021000032953. [DOI] [PubMed] [Google Scholar]
- 327.Pinedo H.M., Zaharko D.S., Bull J.M., Chabner B.A. The reversal of methotrexate cytotoxicity to mouse bone marrow cells by leucovorin and nucleosides. Cancer Res. 1976;36:4418–4424. [PubMed] [Google Scholar]
- 328.Schwartz S., Borner K., Muller K., Martus P., Fischer L., Korfel A., Auton T., Thiel E. Glucarpidase (carboxypeptidase G2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist. 2007;12:1299–1308. doi: 10.1634/theoncologist.12-11-1299. [DOI] [PubMed] [Google Scholar]
- 329.Widemann B.C., Balis F.M., Shalabi A., Boron M., O’Brien M., Cole D.E., Jayaprakash N., Ivy P., Castle V., Muraszko K., Moertel C.L., Trueworthy R., Hermann R.C., Moussa A., Hinton S., Reaman G., Poplack D., Adamson P.C. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst. 2004;96:1557–1559. doi: 10.1093/jnci/djh270. [DOI] [PubMed] [Google Scholar]
- 330.Widemann B.C., Adamson P.C. Understanding and managing methotrexate nephrotoxicity. Oncologist. 2006;11:694–703. doi: 10.1634/theoncologist.11-6-694. [DOI] [PubMed] [Google Scholar]
- 331.Goldman P., Levy C.C. Carboxypeptidase G: Purification and properties. Proc Natl Acad Sci USA. 1967;58:1299–1306. doi: 10.1073/pnas.58.4.1299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 332.Chabner B.A., Johns D.G., Bertino J.R. Enzymatic cleavage of methotrexate provides a method for prevention of drug toxicity. Nature. 1972;239:395–397. doi: 10.1038/239395b0. [DOI] [PubMed] [Google Scholar]
- 333.Abelson H.T., Ensminger W., Rosowsky A., Uren J. Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics. Cancer Treat Rep. 1978;62:1549–1552. [PubMed] [Google Scholar]
- 334.Howell S.B., Blair H.E., Uren J., Frei E., 3rd Hemodialysis and enzymatic cleavage of methotrexate in man. Eur J Cancer. 1978;14:787–792. doi: 10.1016/0014-2964(78)90010-5. [DOI] [PubMed] [Google Scholar]
- 335.Adamson P.C., Balis F.M., McCully C.L., Godwin K.S., Poplack D.G. Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. J Clin Oncol. 1992;10:1359–1364. doi: 10.1200/JCO.1992.10.8.1359. [DOI] [PubMed] [Google Scholar]
- 336.Adamson P.C., Balis F.M., McCully C.L., Godwin K.S., Bacher J.D., Walsh T.J., Poplack D.G. Rescue of experimental intrathecal methotrexate overdose with carboxypeptidase-G2. J Clin Oncol. 1991;9:670–674. doi: 10.1200/JCO.1991.9.4.670. [DOI] [PubMed] [Google Scholar]
- 337.Zoubek A., Zaunschirm H.A., Lion T., Fischmeister G., Vollnhofer G., Gadner H., Pillwein K., Schalhorn A., Bode U. Successful carboxypeptidase G2 rescue in delayed methotrexate elimination due to renal failure. Pediatr Hematol Oncol. 1995;12:471–477. doi: 10.3109/08880019509009477. [DOI] [PubMed] [Google Scholar]
- 338.O’Marcaigh A.S., Johnson C.M., Smithson W.A., Patterson M.C., Widemann B.C., Adamson P.C., McManus M.J. Successful treatment of intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2. Mayo Clin Proc. 1996;71:161–165. doi: 10.4065/71.2.161. [DOI] [PubMed] [Google Scholar]
- 339.Peyriere H., Cociglio M., Margueritte G., Vallat C., Blayac J.P., Hillaire-Buys D. Optimal management of methotrexate intoxication in a child with osteosarcoma. Ann Pharmacother. 2004;38:422–427. doi: 10.1345/aph.1D237. [DOI] [PubMed] [Google Scholar]
- 340.Rowsell S., Pauptit R.A., Tucker A.D., Melton R.G., Blow D.M., Brick P. Crystal structure of carboxypeptidase G2, a bacterial enzyme with applications in cancer therapy. Structure. 1997;5:337–347. doi: 10.1016/S0969-2126(97)00191-3. [DOI] [PubMed] [Google Scholar]
- 341.Widemann B.C., Sung E., Anderson L., Salzer W.L., Balis F.M., Monitjo K.S., McCully C., Hawkins M., Adamson P.C. Pharmacokinetics and metabolism of the methotrexate metabolite 2,4-diamino-N10-methylpteroic acid. J Pharmacol Exp Ther. 2000;294:894–901. [PubMed] [Google Scholar]
- 342.Widemann B.C., Hetherington M.L., Murphy R.F., Balis F.M., Adamson P.C. Carboxypeptidase-G2 rescue in a patient with high dose methotrexate-induced nephrotoxicity. Cancer. 1995;76:521–526. doi: 10.1002/1097-0142(19950801)76:3<521::AID-CNCR2820760325>3.0.CO;2-M. [DOI] [PubMed] [Google Scholar]
- 343.Widemann B.C., Balis F.M., Murphy R.F., Sorensen J.M., Montello M.J., O’Brien M., Adamson P.C. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. J Clin Oncol. 1997;15:2125–2134. doi: 10.1200/JCO.1997.15.5.2125. [DOI] [PubMed] [Google Scholar]
- 344.Schwartz S., Müller K., Fischer L., Korfel A., Jahnke K., Auton T., Thiel E. Favorable outcome in excessive methotrexate (MTX) intoxication after high-dose (HD) MTX therapy by early use of carboxypeptidase G2 (CPG2) J Clin Oncol. 2005;23(16S):8255. [Google Scholar]
- 345.DeAngelis L.M., Tong W.P., Lin S., Fleisher M., Bertino J.R. Carboxypeptidase G2 rescue after high-dose methotrexate. J Clin Oncol. 1996;14:2145–2149. doi: 10.1200/JCO.1996.14.7.2145. [DOI] [PubMed] [Google Scholar]
- 346.Abelson H.T., Ensminger W., Rosowsky A., Uren J. Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics. Cancer Treat Rep. 1978;62:1549–1552. [PubMed] [Google Scholar]
- 347.Widemann B.C., Balis F.M., Shalabi A., Boron M., O’Brien M., Cole D.E., Jayaprakash N., Ivy P., Castle V., Muraszko K., Moertel C.L., Trueworthy R., Hermann R.C., Moussa A., Hinton S., Reaman G., Poplack D., Adamson P.C. Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2. J Natl Cancer Inst. 2004;96:1557–1559. doi: 10.1093/jnci/djh270. [DOI] [PubMed] [Google Scholar]
- 348.Hempel G., Lingg R., Boos J. Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: Implications for the application in case of methotrexate intoxications. Cancer Chemother Pharmacol. 2005;55:347–353. doi: 10.1007/s00280-004-0910-2. [DOI] [PubMed] [Google Scholar]
- 349.Fotoohi K., Skarby T., Soderhall S., Peterson C., Albertioni F. Interference of 7-hydroxymethotrexate with the determination of methotrexate in plasma samples from children with acute lymphoblastic leukemia employing routine clinical assays. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;817:139–144. doi: 10.1016/j.jchromb.2004.11.037. [DOI] [PubMed] [Google Scholar]
- 350.European Medicines Agency . Pre-authorisation Evaluation of Medicines for Human Use. London, UK: European Medicines Agency (EMEA); 2008. [Google Scholar]
- 351.Sherwood R.F., Melton R.G., Alwan S.M., Hughes P. Purification and properties of carboxypeptidase G2 from Pseudomonas sp. strain RS-16. Use of a novel triazine dye affinity method. Eur J Biochem. 1985;148:447–453. doi: 10.1111/j.1432-1033.1985.tb08860.x. [DOI] [PubMed] [Google Scholar]
- 352.Albertson T.E., Dawson A., de Latorre F., Hoffman R.S., Hollander J.E., Jaeger A., Kerns W.R., 2nd, Martin T.G., Ross M.P. TOX-ACLS: Toxicologic-oriented advanced cardiac life support. Ann Emerg Med. 2001;37:78–90. doi: 10.1067/mem.2001.114174. [DOI] [PubMed] [Google Scholar]
- 353.Ansell J., Hirsh J., Hylek E., Jacobson A., Crowther M., Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133:160S–198S. doi: 10.1378/chest.08-0670. [DOI] [PubMed] [Google Scholar]
- 354.Hirsh J., Bauer K.A., Donati M.B., Gould M., Samama M.M., Weitz J.I. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133:141S–159S. doi: 10.1378/chest.08-0689. [DOI] [PubMed] [Google Scholar]
- 355.Warkentin T.E., Greinacher A., Koster A., Lincoff A.M. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2008;133:340S–380S. doi: 10.1378/chest.08-0677. [DOI] [PubMed] [Google Scholar]
- 356.Dager W.E., Sanoski C.A., Wiggins B.S., Tisdale J.E. Pharmacotherapy considerations in advanced cardiac life support. Pharmacotherapy. 2006;26:1703–1729. doi: 10.1592/phco.26.12.1703. [DOI] [PubMed] [Google Scholar]
- 357.Dhein S., van Koppen C.J., Brodde O.E. Muscarinic receptors in the mammalian heart. Pharmacol Res. 2001;44:161–182. doi: 10.1006/phrs.2001.0835. [DOI] [PubMed] [Google Scholar]
- 358.Howarth D.M., Dawson A.H., Smith A.J., Buckley N., Whyte I.M. Calcium channel blocking drug overdose: An Australian series. Hum Exp Toxicol. 1994;13:161–166. doi: 10.1177/096032719401300304. [DOI] [PubMed] [Google Scholar]
- 359.Kerns W., 2nd Management of β-adrenergic blocker and calcium channel antagonist toxicity. Emerg Med Clin North Am. 2007;25:309–331. doi: 10.1016/j.emc.2007.02.001. [DOI] [PubMed] [Google Scholar]
- 360.Sim M.T., Stevenson F.T. A fatal case of iatrogenic hypercalcemia after calcium channel blocker overdose. J Med Toxicol. 2008;4:25–29. doi: 10.1007/BF03160947. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 361.Salhanick S.D., Shannon M.W. Management of calcium channel antagonist overdose. Drug Saf. 2003;26:65–79. doi: 10.2165/00002018-200326020-00001. [DOI] [PubMed] [Google Scholar]
- 362.APP . Calcium Gluconate Injection, USP 10%. Schaumburg, IL: APP Pharmaceuticals, LLC; 2007. [Google Scholar]
- 363.Nola G.T., Pope S., Harrison D.C. Assessment of the synergistic relationship between serum calcium and digitalis. Am Heart J. 1970;79:499. doi: 10.1016/0002-8703(70)90255-3. [DOI] [PubMed] [Google Scholar]
- 364.Ericksona C.P., Olson K.R. Case files of the medical toxicology fellowship of the California poison control system-San Francisco: Calcium plus digoxin-more taboo than toxic? J Med Toxicol. 2008;4:33–39. doi: 10.1007/BF03160949. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 365.Wenger T.L., Butler V.P., Jr, Haber E., Smith T.W. Treatment of 63 severely digitalis-toxic patients with digoxin-specific antibody fragments. J Am Coll Cardiol. 1985;5:118A–123A. doi: 10.1016/S0735-1097(85)80471-X. [DOI] [PubMed] [Google Scholar]
- 366.Smith T.W., Haber E., Yeatman L., Butler V.P., Jr Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med. 1976;294:797–800. doi: 10.1056/NEJM197604082941501. [DOI] [PubMed] [Google Scholar]
- 367.Antman E.M., Wenger T.L., Butler V.P., Jr, Haber E., Smith T.W. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990;81:1744–1752. doi: 10.1161/01.cir.81.6.1744. [DOI] [PubMed] [Google Scholar]
- 368.Lapostolle F., Borron S.W., Verdier C., Taboulet P., Guerrier G., Adnet F., Clemessy J.L., Bismuth C., Baud F.J. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med. 2008;36:3014–3018. doi: 10.1097/CCM.0b013e31818b341c. [DOI] [PubMed] [Google Scholar]
- 369.Woolf A.D., Wenger T., Smith T.W., Lovejoy F.H., Jr The use of digoxin-specific Fab fragments for severe digitalis intoxication in children. N Engl J Med. 1992;326:1739–1744. doi: 10.1056/NEJM199206253262604. [DOI] [PubMed] [Google Scholar]
- 370.Smith T.W. Review of clinical experience with digoxin immune Fab (ovine) Am J Emerg Med. 1991;9:1–6. doi: 10.1016/0735-6757(91)90159-H. [DOI] [PubMed] [Google Scholar]
- 371.Bateman D.N. Digoxin-specific antibody fragments: How much and when? Toxicol Rev. 2004;23:135–143. doi: 10.2165/00139709-200423030-00001. [DOI] [PubMed] [Google Scholar]
- 372.Ujhelyi M.R., Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet. 1995;28:483–493. doi: 10.2165/00003088-199528060-00006. [DOI] [PubMed] [Google Scholar]
- 373.Mehta R.N., Mehta N.J., Gulati A. Late rebound digoxin toxicity after digoxin-specific antibody Fab fragments therapy in anuric patient. J Emerg Med. 2002;22:203–206. doi: 10.1016/S0736-4679(01)00465-6. [DOI] [PubMed] [Google Scholar]
- 374.Bosse G.M., Pope T.M. Recurrent digoxin overdose and treatment with digoxin-specific Fab antibody fragments. J Emerg Med. 1994;12:179–185. doi: 10.1016/0736-4679(94)90696-3. [DOI] [PubMed] [Google Scholar]
- 375.Camphausen C., Haas N.A., Mattke A.C. Successful treatment of oleander intoxication (cardiac glycosides) with digoxin-specific Fab antibody fragments in a 7-year-old child: Case report and review of literature. Z Kardiol. 2005;94:817–823. doi: 10.1007/s00392-005-0293-3. [DOI] [PubMed] [Google Scholar]
- 376.Brubacher J.R., Lachmanen D., Ravikumar P.R., Hoffman R.S. Efficacy of digoxin specific Fab fragments (Digibind) in the treatment of toad venom poisoning. Toxicon. 1999;37:931–942. doi: 10.1016/S0041-0101(98)00224-4. [DOI] [PubMed] [Google Scholar]
- 377.Ali S., Drucker D.J. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab. 2009;296:E415–421. doi: 10.1152/ajpendo.90887.2008. [DOI] [PubMed] [Google Scholar]
- 378.Eli Lilly and. Company . Information for the Physician. Glucagon for Injection (rDNA origin) Indianapolis, IN: Eli Lilly and Company; 2005. [Google Scholar]
- 379.Shepherd G. Treatment of poisoning caused by β-adrenergic and calcium-channel blockers. Am J Health Syst Pharm. 2006;63:1828–1835. doi: 10.2146/ajhp060041. [DOI] [PubMed] [Google Scholar]
- 380.Sauvadet A., Rohn T., Pecker F., Pavoine C. Arachidonic acid drives mini-glucagon action in cardiac cells. J Biol Chem. 1997;272:12437–12445. doi: 10.1074/jbc.272.19.12437. [DOI] [PubMed] [Google Scholar]
- 381.Parmley W.W., Glick G., Sonnenblick E.H. Cardiovascular effects of glucagon in man. N Engl J Med. 1968;279:12–17. doi: 10.1056/NEJM196807042790103. [DOI] [PubMed] [Google Scholar]
- 382.Boyd R., Ghosh A. Towards evidence based emergency medicine: Best BETs from the Manchester Royal Infirmary. Glucagon for the treatment of symptomatic β blocker overdose. Emerg Med J. 2003;20:266–267. doi: 10.1136/emj.20.3.266. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 383.Lee J. Glucagon use in symptomatic β blocker overdose. Emerg Med J. 2004;21:755. doi: 10.1136/emj.2003.004945. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 384.Stone C.K., May W.A., Carroll R. Treatment of verapamil overdose with glucagon in dogs. Ann Emerg Med. 1995;25:369–374. doi: 10.1016/S0196-0644(95)70297-0. [DOI] [PubMed] [Google Scholar]
- 385.Walter F.G., Frye G., Mullen J.T., Ekins B.R., Khasigian P.A. Amelioration of nifedipine poisoning associated with glucagon therapy. Ann Emerg Med. 1993;22:1234–1237. doi: 10.1016/S0196-0644(05)80998-9. [DOI] [PubMed] [Google Scholar]
- 386.Zaritsky A.L., Horowitz M., Chernow B. Glucagon antagonism of calcium channel blocker-induced myocardial dysfunction. Crit Care Med. 1988;16:246–251. doi: 10.1097/00003246-198803000-00008. [DOI] [PubMed] [Google Scholar]
- 387.Kline J.A., Leonova E., Williams T.C., Schroeder J.D., Watts J.A. Myocardial metabolism during ing graded intraportal verapamil infusion in awake dogs. J Cardiovasc Pharmacol. 1996;27:719–726. doi: 10.1097/00005344-199605000-00015. [DOI] [PubMed] [Google Scholar]
- 388.Kline J.A., Leonova E., Raymond R.M. Beneficial myocardial metabolic effects of insulin during verapamil toxicity in the anesthetized canine. Crit Care Med. 1995;23:1251–1263. doi: 10.1097/00003246-199507000-00016. [DOI] [PubMed] [Google Scholar]
- 389.Oldenburg O., Eggebrecht H., Gutersohn A., Schaar J., Brauck K., Haude M., Erbel R., Baumgart D. Myocardial lactate release after intracoronary verapamil application in humans: Acute effects of intracoronary verapamil on systemic and coronary hemodynamics, myocardial metabolism, and norepinephrine levels. Cardiovasc Drugs Ther. 2001;15:55–61. doi: 10.1023/A:1011162818809. [DOI] [PubMed] [Google Scholar]
- 390.Puskarich M.A., Runyon M.S., Trzeciak S., Kline J.A., Jones A.E. Effect of glucose-insulin-potassium infusion on mortality in critical care settings: A systematic review and meta-analysis. J Clin Pharmacol. 2009;49:758–767. doi: 10.1177/0091270009334375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 391.Schipke JD, Friebe R, Gams E. Forty years of glucose-insulin-potassium (GIK) in cardiac surgery: A review of randomized, controlled trials. Eur J Cardiothorac Surg. 92006;29:479–485. doi: 10.1016/j.ejcts.2006.01.023. [DOI] [PubMed] [Google Scholar]
- 392.Koskenkari J.K., Kaukoranta P.K., Rimpilainen J., Vainionpaa V., Ohtonen P.P., Surcel H.M., Juvonen T., Ala-Kokko T.I. Anti-inflammatory effect of high-dose insulin treatment after urgent coronary revascularization surgery. Acta Anaesthesiol Scand. 2006;50:962–969. doi: 10.1111/j.1399-6576.2006.01100.x. [DOI] [PubMed] [Google Scholar]
- 393.Doenst T., Bothe W., Beyersdorf F. Therapy with insulin in cardiac surgery: Controversies and possible solutions. Ann Thorac Surg. 2003;75:721–728. doi: 10.1016/S0003-4975(02)04698-2. [DOI] [PubMed] [Google Scholar]
- 394.Svedjeholm R., Ekroth R., Joachimsson P.O., Tyden H. High-dose insulin improves the efficacy of dopamine early after cardiac surgery. A study of myocardial performance and oxygen consumption. Scand J Thorac Cardiovasc Surg. 1991;25:215–221. doi: 10.3109/14017439109099042. [DOI] [PubMed] [Google Scholar]
- 395.Kline J.A., Raymond R.M., Leonova E.D., Williams T.C., Watts J.A. Insulin improves heart function and metabolism during non-ischemic cardiogenic shock in awake canines. Cardiovasc Res. 1997;34:289–298. doi: 10.1016/S0008-6363(97)00022-9. [DOI] [PubMed] [Google Scholar]
- 396.Kerns W., 2nd, Schroeder D., Williams C., Tomaszewski C., Raymond R. Insulin improves survival in a canine model of acute β-blocker toxicity. Ann Emerg Med. 1997;29:748–757. doi: 10.1016/S0196-0644(97)70196-3. [DOI] [PubMed] [Google Scholar]
- 397.Holger J.S., Engebretsen K.M., Fritzlar S.J., Patten L.C., Harris C.R., Flottemesch T.J. Insulin versus vasopressin and epinephrine to treat β-blocker toxicity. Clin Toxicol. 2007;45:396–401. doi: 10.1080/15563650701285412. [DOI] [PubMed] [Google Scholar]
- 398.Greene S.L., Gawarammana I., Wood D.M., Jones A.L., Dargan P.I. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: A prospective observational study. Intensive Care Med. 2007;33:2019–2024. doi: 10.1007/s00134-007-0768-y. [DOI] [PubMed] [Google Scholar]
- 399.Cohen V, Jellinek SP, Fancher L, Sangwan G, Wakslak M, Marquart E, Farahani C (2009) Tarka(R) (trandolapril/verapamil hydrochloride extended-release) overdose. J Emerg Med, in press [DOI] [PubMed]
- 400.Prigeon R.L., Roder M.E., Porte D., Jr, Kahn S.E. The effect of insulin dose on the measurement of insulin sensitivity by the minimal model technique. Evidence for saturable insulin transport in humans. J Clin Invest. 1996;97:501–507. doi: 10.1172/JCI118441. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 401.Mokshagundam S.P., Peiris A.N., Stagner J.I., Gingerich R.L., Samols E. Interstitial insulin during euglycemic-hyperinsulinemic clamp in obese and lean individuals. Metabolism. 1996;45:951–956. doi: 10.1016/S0026-0495(96)90261-9. [DOI] [PubMed] [Google Scholar]
- 402.Natali A., Gastaldelli A., Camastra S., Sironi A.M., Toschi E., Masoni A., Ferrannini E., Mari A. Dose-response characteristics of insulin action on glucose metabolism: A non-steady-state approach. Am J Physiol Endocrinol Metab. 2000;278:E794–801. doi: 10.1152/ajpendo.2000.278.5.E794. [DOI] [PubMed] [Google Scholar]
- 403.Foxall G., McCahon R., Lamb J., Hardman J.G., Bedforth N.M. Levobupivacaine-induced seizures and cardiovascular collapse treated with Intralipid. Anaesthesia. 2007;62:516–518. doi: 10.1111/j.1365-2044.2007.05065.x. [DOI] [PubMed] [Google Scholar]
- 404.Groban L., Deal D.D., Vernon J.C., James R.L., Butterworth J. Cardiac resuscitation after incremental overdosage with lidocaine, bupivacaine, levobupivacaine, and ropivacaine in anesthetized dogs. Anesth Analg. 2001;92:37–43. doi: 10.1097/00000539-200101000-00008. [DOI] [PubMed] [Google Scholar]
- 405.Weinberg G., Ripper R., Feinstein D.L., Hoffman W. Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med. 2003;28:198–202. doi: 10.1053/rapm.2003.50041. [DOI] [PubMed] [Google Scholar]
- 406.Weinberg G.L., Di Gregorio G., Ripper R., Kelly K., Massad M., Edelman L., Schwartz D., Shah N., Zheng S., Feinstein D.L. Resuscitation with lipid versus epinephrine in a rat model of bupivacaine overdose. Anesthesiology. 2008;108:907–913. doi: 10.1097/ALN.0b013e31816d91d2. [DOI] [PubMed] [Google Scholar]
- 407.Warren J.A., Thoma R.B., Georgescu A., Shah S.J. Intravenous lipid infusion in the successful resuscitation of local anesthetic-induced cardiovascular collapse after supraclavicular brachial plexus block. Anesth Analg. 2008;106:1578–1580. doi: 10.1213/01.ane.0000281434.80883.88. [DOI] [PubMed] [Google Scholar]
- 408.Litz R.J., Popp M., Stehr S.N., Koch T. Successful resuscitation of a patient with ropivacaineinduced asystole after axillary plexus block using lipid infusion. Anaesthesia. 2006;61:800–801. doi: 10.1111/j.1365-2044.2006.04740.x. [DOI] [PubMed] [Google Scholar]
- 409.Litz R.J., Roessel T., Heller A.R., Stehr S.N. Reversal of central nervous system and cardiac toxicity after local anesthetic intoxication by lipid emulsion injection. Anesth Analg. 2008;106:1575–1577. doi: 10.1213/ane.0b013e3181683dd7. [DOI] [PubMed] [Google Scholar]
- 410.Ludot H., Tharin J.Y., Belouadah M., Mazoit J.X., Malinovsky J.M. Successful resuscitation after ropivacaine and lidocaine-induced ventricular arrhythmia following posterior lumbar plexus block in a child. Anesth Analg. 2008;106:1572–1574. doi: 10.1213/01.ane.0000286176.55971.f0. [DOI] [PubMed] [Google Scholar]
- 411.Finn S.D., Uncles D.R., Willers J., Sable N. Early treatment of a quetiapine and sertraline overdose with Intralipid. Anaesthesia. 2009;64:191–194. doi: 10.1111/j.1365-2044.2008.05744.x. [DOI] [PubMed] [Google Scholar]
- 412.Sirianni A.J., Osterhoudt K.C., Calello D.P., Muller A.A., Waterhouse M.R., Goodkin M.B., Weinberg G.L., Henretig F.M. Use of lipid emulsion in the resuscitation of a patient with prolonged cardiovascular collapse after overdose of bupropion and lamotrigine. Ann Emerg Med. 2008;51:412–415. doi: 10.1016/j.annemergmed.2007.06.004. [DOI] [PubMed] [Google Scholar]
- 413.Harvey M., Cave G. Intralipid outperforms sodium bicarbonate in a rabbit model of clomipramine toxicity. Ann Emerg Med. 2007;49:178–185. doi: 10.1016/j.annemergmed.2006.07.016. [DOI] [PubMed] [Google Scholar]
- 414.Harvey M.G., Cave G.R. Intralipid infusion ameliorates propranolol-induced hypotension in rabbits. J Med Toxicol. 2008;4:71–76. doi: 10.1007/BF03160958. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 415.Bania T.C., Chu J., Perez E., Su M., Hahn I.H. Hemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, calcium, and saline. Acad Emerg Med. 2007;14:105–111. doi: 10.1111/j.1553-2712.2007.tb01752.x. [DOI] [PubMed] [Google Scholar]
- 416.Cave G., Harvey M.G., Castle C.D. Intralipid ameliorates thiopentone induced respiratory depression in rats: Investigative pilot study. Emerg Med Australas. 2005;17:180–181. doi: 10.1111/j.1742-6723.2005.00714.x. [DOI] [PubMed] [Google Scholar]
- 417.Florian J.P., Pawelczyk J.A. Non-esterified fatty acids increase arterial pressure via central sympathetic activation in humans. Clin Sci. 2009;118:61–69. doi: 10.1042/CS20090063. [DOI] [PubMed] [Google Scholar]
- 418.Stehr S.N., Ziegeler J.C., Pexa A., Oertel R., Deussen A., Koch T., Hubler M. The effects of lipid infusion on myocardial function and bioenergetics in l-bupivacaine toxicity in the isolated rat heart. Anesth Analg. 2007;104:186–192. doi: 10.1213/01.ane.0000248220.01320.58. [DOI] [PubMed] [Google Scholar]
- 419.The Association of Anaesthetists of Great Britain & Ireland (2007) Guidelines for the Management of Severe Local Anaesthetic Toxicity (http://www.aagbi.org/publications/guidelines/docs/latoxicity07.pdf, accessed May 19, 2009)
- 420.Felice K., Schumann H. Intravenous lipid emulsion for local anesthetic toxicity: A review of the literature. J Med Toxicol. 2008;4:184–191. doi: 10.1007/BF03161199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 421.Marwick P.C., Levin A.I., Coetzee A.R. Recurrence of cardiotoxicity after lipid rescue from bupivacaine-induced cardiac arrest. Anesth Analg. 2009;108:1344–1346. doi: 10.1213/ane.0b013e3181979e17. [DOI] [PubMed] [Google Scholar]
- 422.Harvey M., Cave G., Kazemi A. Intralipid infusion diminishes return of spontaneous circulation after hypoxic cardiac arrest in rabbits. Anesth Analg. 2009;108:1163–1168. doi: 10.1213/ane.0b013e31819367ba. [DOI] [PubMed] [Google Scholar]
- 423.Mayr V.D., Mitterschiffthaler L., Neurauter A., Gritsch C., Wenzel V., Muller T., Luckner G., Lindner K.H., Strohmenger H.U. A comparison of the combination of epinephrine and vasopressin with lipid emulsion in a porcine model of asphyxial cardiac arrest after intravenous injection of bupivacaine. Anesth Analg. 2008;106:1566–1571. doi: 10.1213/01.ane.0000278866.01963.79. [DOI] [PubMed] [Google Scholar]
- 424.Mazoit J.X., Le Guen R., Beloeil H., Benhamou D. Binding of long-lasting local anesthetics to lipid emulsions. Anesthesiology. 2009;110:380–386. doi: 10.1097/ALN.0b013e318194b252. [DOI] [PubMed] [Google Scholar]
- 425.De Bruin M.L., Langendijk P.N., Koopmans R.P., Wilde A.A., Leufkens H.G., Hoes A.W. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs. Br J Clin Pharmacol. 2007;63:216–223. doi: 10.1111/j.1365-2125.2006.02722.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 426.Gupta A., Lawrence A.T., Krishnan K., Kavinsky C.J., Trohman R.G. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsade de pointes. Am Heart J. 2007;153:891–899. doi: 10.1016/j.ahj.2007.01.040. [DOI] [PubMed] [Google Scholar]
- 427.Khan I.A., Gowda R.M. Novel therapeutics for treatment of long-QT syndrome and torsade de pointes. Int J Cardiol. 2004;95:1–6. doi: 10.1016/j.ijcard.2003.04.018. [DOI] [PubMed] [Google Scholar]
- 428.Sasyniuk B.I., Jhamandas V. Mechanism of reversal of toxic effects of amitriptyline on cardiac Purkinje fibers by sodium bicarbonate. J Pharmacol Exp Ther. 1984;231:387–394. [PubMed] [Google Scholar]
- 429.Sasyniuk B.I., Jhamandas V., Valois M. Experimental amitriptyline intoxication: Treatment of cardiac toxicity with sodium bicarbonate. Ann Emerg Med. 1986;15:1052–1059. doi: 10.1016/S0196-0644(86)80128-7. [DOI] [PubMed] [Google Scholar]
- 430.Brown T.C. Tricyclic antidepressant overdosage: Experimental studies on the management of circulatory complications. Clin Toxicol. 1976;9:255–272. doi: 10.3109/15563657608988129. [DOI] [PubMed] [Google Scholar]
- 431.Boehnert M.T., Lovejoy F.H., Jr Value of the QRS duration versus the serum drug level in predicting seizures and ventricular arrhythmias after an acute overdose of tricyclic antidepressants. N Engl J Med. 1985;313:474–479. doi: 10.1056/NEJM198508223130804. [DOI] [PubMed] [Google Scholar]
- 432.Niemann J.T., Bessen H.A., Rothstein R.J., Laks M.M. Electrocardiographic criteria for tricyclic antidepressant cardiotoxicity. Am J Cardiol. 1986;57:1154–1159. doi: 10.1016/0002-9149(86)90691-0. [DOI] [PubMed] [Google Scholar]
- 433.Liebelt E.L., Francis P.D., Woolf A.D. ECG lead aVR versus QRS interval in predicting seizures and arrhythmias in acute tricyclic antidepressant toxicity. Ann Emerg Med. 1995;26:195–201. doi: 10.1016/S0196-0644(95)70151-6. [DOI] [PubMed] [Google Scholar]
- 434.Pentel P.R., Keyler D.E. Effects of high dose α-1-acid glycoprotein on desipramine toxicity in rats. J Pharmacol Exp Ther. 1988;246:1061–1066. [PubMed] [Google Scholar]
- 435.Taboulet P., Michard F., Muszynski J., Galliot-Guilley M., Bismuth C. Cardiovascular repercussions of seizures during cyclic antidepressant poisoning. J Toxicol Clin Toxicol. 1995;33:205–211. doi: 10.3109/15563659509017985. [DOI] [PubMed] [Google Scholar]
- 436.Knudsen K., Abrahamsson J. Epinephrine and sodium bicarbonate independently and additively increase survival in experimental amitriptyline poisoning. Crit Care Med. 1997;25:669–674. doi: 10.1097/00003246-199704000-00019. [DOI] [PubMed] [Google Scholar]
- 437.Bessen H.A., Niemann J.T. Improvement of cardiac conduction after hyperventilation in tricyclic antidepressant overdose. J Toxicol Clin Toxicol. 1985;23:537–546. doi: 10.3109/15563658508990655. [DOI] [PubMed] [Google Scholar]
- 438.McCabe J.L., Cobaugh D.J., Menegazzi J.J., Fata J. Experimental tricyclic antidepressant toxicity: A randomized, controlled comparison of hypertonic saline solution, sodium bicarbonate, and hyperventilation. Ann Emerg Med. 1998;32:329–333. doi: 10.1016/S0196-0644(98)70009-5. [DOI] [PubMed] [Google Scholar]
- 439.McKinney P.E., Rasmussen R. Reversal of severe tricyclic antidepressant-induced cardiotoxicity with intravenous hypertonic saline solution. Ann Emerg Med. 2003;42:20–24. doi: 10.1067/mem.2003.233. [DOI] [PubMed] [Google Scholar]
- 440.Brown T.C. Sodium bicarbonate treatment for tricyclic antidepressant arrhythmias in children. Med J Aust. 1976;2:380–382. doi: 10.5694/j.1326-5377.1976.tb130260.x. [DOI] [PubMed] [Google Scholar]
- 441.Woolf A.D., Erdman A.R., Nelson L.S., Caravati E.M., Cobaugh D.J., Booze L.L., Wax P.M., Manoguerra A.S., Scharman E.J., Olson K.R., Chyka P.A., Christianson G., Troutman W.G. Tricyclic antidepressant poisoning: An evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2007;45:203–233. doi: 10.1080/15563650701226192. [DOI] [PubMed] [Google Scholar]
- 442.Sharma A.N., Hexdall A.H., Chang E.K., Nelson L.S., Hoffman R.S. Diphenhydramine-induced wide complex dysrhythmia responds to treatment with sodium bicarbonate. Am J Emerg Med. 2003;21:212–215. doi: 10.1016/S0735-6757(02)42248-6. [DOI] [PubMed] [Google Scholar]
- 443.Stork C.M., Redd J.T., Fine K., Hoffman R.S. Propoxyphene-induced wide QRS complex dysrhythmia responsive to sodium bicarbonate — A case report. J Toxicol Clin Toxicol. 1995;33:179–183. doi: 10.3109/15563659509000470. [DOI] [PubMed] [Google Scholar]
- 444.Kalimullah E.A., Bryant S.M. Case files of the medical toxicology fellowship at the toxikon consortium in Chicago: Cocaine-associated wide-complex dysrhythmias and cardiac arrest — Treatment nuances and controversies. J Med Toxicol. 2008;4:277–283. doi: 10.1007/BF03161213. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 445.Mailloux D., Adar E., Su M. Acute carbamazepine toxicity associated with a widened QRS interval treated with intravenous sodium bicarbonate. Clin Toxicol. 2005;43:505–506. [Google Scholar]
- 446.Wills B.K., Zell-Kanter M., Aks S.E. Bupropion-associated QRS prolongation unresponsive to sodium bicarbonate therapy. Am J Ther. 2009;16:193–196. doi: 10.1097/MJT.0b013e3180a5bd83. [DOI] [PubMed] [Google Scholar]
- 447.Bosse G.M., Spiller H.A., Collins A.M. A fatal case of venlafaxine overdose. J Med Toxicol. 2008;4:18–20. doi: 10.1007/BF03160945. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 448.Buckley N.A., Whyte I.M., Dawson A.H. Self-poisoning with lamotrigine. Lancet. 1993;342:1552–1553. doi: 10.1016/S0140-6736(05)80120-5. [DOI] [PubMed] [Google Scholar]
- 449.Pierog J., Kane B., Kane K., Donovan J.W. Management of isolated yew berry toxicity with sodium bicarbonate: A case report in treatment efficacy. J Med Toxicol. 2009;5:84–89. doi: 10.1007/BF03161094. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 450.Schwartz M., Patel M., Kazzi Z., Morgan B. Cardiotoxicity after massive amantadine overdose. J Med Toxicol. 2008;4:173–179. doi: 10.1007/BF03161197. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 451.Clarke S.F., Dargan P.I., Jones A.L. Naloxone in opioid poisoning: Walking the tightrope. Emerg Med J. 2005;22:612–616. doi: 10.1136/emj.2003.009613. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 452.Bracken M.B., Shepard M.J., Collins W.F., Holford T.R., Young W., Baskin D.S., Eisenberg H.M., Flamm E., Leo-Summers L., Maroon J. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322:1405–1411. doi: 10.1056/NEJM199005173222001. [DOI] [PubMed] [Google Scholar]
- 453.Buajordet I., Naess A.C., Jacobsen D., Brors O. Adverse events after naloxone treatment of episodes of suspected acute opioid overdose. Eur J Emerg Med. 2004;11:19–23. doi: 10.1097/00063110-200402000-00004. [DOI] [PubMed] [Google Scholar]
- 454.Mills C.A., Flacke J.W., Flacke W.E., Bloor B.C., Liu M.D. Narcotic reversal in hypercapnic dogs: Comparison of naloxone and nalbuphine. Can J Anaesth. 1990;37:238–244. doi: 10.1007/BF03005476. [DOI] [PubMed] [Google Scholar]
- 455.International Liaison Committee on Resuscitation The ILCOR consensus on science with treatment recommendations for pediatric and neonatal patients: Neonatal resuscitation. Pediatrics. 2006;117:e978–988. doi: 10.1542/peds.2006-0350. [DOI] [PubMed] [Google Scholar]
- 456.Deshpande G., Gill A. Cardiac arrest following naloxone in an extremely preterm neonate. Eur J Pediatr. 2009;168:115–117. doi: 10.1007/s00431-008-0720-3. [DOI] [PubMed] [Google Scholar]
- 457.Hoffman J.R., Schriger D.L., Luo J.S. The empiric use of naloxone in patients with altered mental status: A reappraisal. Ann Emerg Med. 1991;20:246–252. doi: 10.1016/S0196-0644(05)80933-3. [DOI] [PubMed] [Google Scholar]
- 458.Goldfrank L., Weisman R.S., Errick J.K., Lo M.W. A dosing nomogram for continuous infusion intravenous naloxone. Ann Emerg Med. 1986;15:566–570. doi: 10.1016/S0196-0644(86)80994-5. [DOI] [PubMed] [Google Scholar]
- 459.Geib A.J., Babu K., Ewald M.B., Boyer E.W. Adverse effects in children after unintentional buprenorphine exposure. Pediatrics. 2006;118:1746–1751. doi: 10.1542/peds.2006-0948. [DOI] [PubMed] [Google Scholar]
- 460.Van Dorp E., Yassen A., Sarton E., Romberg R., Olofsen E., Teppema L., Danhof M., Dahan A. Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006;105:51–57. doi: 10.1097/00000542-200607000-00012. [DOI] [PubMed] [Google Scholar]
- 461.Horowitz R., Mazor S.S., Aks S.E., Leikin J.B. Accidental clonidine patch ingestion in a child. Am J Ther. 2005;12:272–274. [PubMed] [Google Scholar]
- 462.Seger D.L. Clonidine toxicity revisited. J Toxicol Clin Toxicol. 2002;40:145–155. doi: 10.1081/CLT-120004402. [DOI] [PubMed] [Google Scholar]
- 463.Varon J., Duncan S.R. Naloxone reversal of hypotension due to captopril overdose. Ann Emerg Med. 1991;20:1125–1127. doi: 10.1016/S0196-0644(05)81389-7. [DOI] [PubMed] [Google Scholar]
- 464.Barr C.S., Payne R., Newton R.W. Profound prolonged hypotension following captopril overdose. Postgrad Med J. 1991;67:953–954. doi: 10.1136/pgmj.67.792.953-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 465.Millar J.A., Sturani A., Rubin P.C., Lawrie C., Reid J.L. Attenuation of the antihypertensive effect of captopril by the opioid receptor antagonist naloxone. Clin Exp Pharmacol Physiol. 1983;10:253–259. doi: 10.1111/j.1440-1681.1983.tb00192.x. [DOI] [PubMed] [Google Scholar]
- 466.Ajayi A.A., Campbell B.C., Rubin P.C., Reid J.L. Effect of naloxone on the actions of captopril. Clin Pharmacol Ther. 1985;38:560–565. doi: 10.1038/clpt.1985.224. [DOI] [PubMed] [Google Scholar]
- 467.Bernini G., Taddei S., Graziadei L., Pedrinelli R., Salvetti A. Naloxone does not modify the antihypertensive effect of captopril in essential hypertensive patients. J Hypertens Suppl. 1985;3:117–119. doi: 10.1097/00004872-198504000-00003. [DOI] [PubMed] [Google Scholar]
- 468.Lopez-Romero B., Evrard G., Durant F., Sevrin M., George P. Molecular structure and stereoelectronic properties of sarmazenil — A weak inverse agonist at the omega modulatory sites (benzodiazepine receptors): Comparison with bretazenil and flumazenil. Bioorg Med Chem. 1998;6:1745–1757. doi: 10.1016/S0968-0896(98)00117-5. [DOI] [PubMed] [Google Scholar]
- 469.Dunton A.W., Schwam E., Pitman V., McGrath J., Hendler J., Siegel J. Flumazenil: US clinical pharmacology studies. Eur J Anaesthesiol. 1988;2:81–95. [PubMed] [Google Scholar]
- 470.Amrein R., Hetzel W., Hartmann D., Lorscheid T. Clinical pharmacology of flumazenil. Eur J Anaesthesiol Suppl. 1988;2:65–80. [PubMed] [Google Scholar]
- 471.Mora C.T., Torjman M., White P.F. Sedative and ventilatory effects of midazolam infusion: Effect of flumazenil reversal. Can J Anaesth. 1995;42:677–684. doi: 10.1007/BF03012664. [DOI] [PubMed] [Google Scholar]
- 472.Flogel C.M., Ward D.S., Wada D.R., Ritter J.W. The effects of large-dose flumazenil on midazolam-induced ventilatory depression. Anesth Analg. 1993;77:1207–1214. [PubMed] [Google Scholar]
- 473.Shalansky S.J., Naumann T.L., Englander F.A. Effect of flumazenil on benzodiazepine-induced respiratory depression. Clin Pharm. 1993;12:483–487. [PubMed] [Google Scholar]
- 474.Dahaba A.A., Bornemann H., Rehak P.H., Wang G., Wu X.M., Metzler H. Effect of flumazenil on bispectral index monitoring in unpremedicated patients. Anesthesiology. 2009;110:1036–1040. doi: 10.1097/ALN.0b013e31819db2c4. [DOI] [PubMed] [Google Scholar]
- 475.Polc P. Electrophysiology of benzodiazepine receptor ligands: Multiple mechanisms and sites of action. Prog Neurobiol. 1988;31:349–423. doi: 10.1016/0301-0082(88)90014-7. [DOI] [PubMed] [Google Scholar]
- 476.Morgan M.M., Levin E.D., Liebeskind J.C. Characterization of the analgesic effects of the benzodiazepine antagonist, Ro 15-1788. Brain Res. 1987;415:367–370. doi: 10.1016/0006-8993(87)90222-8. [DOI] [PubMed] [Google Scholar]
- 477.Gueye P.N., Hoffman J.R., Taboulet P., Vicaut E., Baud F.J. Empiric use of flumazenil in comatose patients: Limited applicability of criteria to define low risk. Ann Emerg Med. 1996;27:730–735. doi: 10.1016/S0196-0644(96)70191-9. [DOI] [PubMed] [Google Scholar]
- 478.Weinbroum A., Rudick V., Sorkine P., Nevo Y., Halpern P., Geller E., Niv D. Use of flumazenil in the treatment of drug overdose: A double-blind and open clinical study in 110 patients. Crit Care Med. 1996;24:199–206. doi: 10.1097/00003246-199602000-00004. [DOI] [PubMed] [Google Scholar]
- 479.Spivey W.H. Flumazenil and seizures: Analysis of 43 cases. Clin Ther. 1992;14:292–305. [PubMed] [Google Scholar]
- 480.Anonymous Treatment of benzodiazepine overdose with flumazenil. The Flumazenil in Benzodiazepine Intoxication Multicenter Study Group. Clin Ther. 1992;14:978–995. [PubMed] [Google Scholar]
- 481.Weinbroum A.A., Flaishon R., Sorkine P., Szold O., Rudick V. A risk-benefit assessment of flumazenil in the management of benzodiazepine overdose. Drug Saf. 1997;17:181–196. doi: 10.2165/00002018-199717030-00004. [DOI] [PubMed] [Google Scholar]
- 482.Nau H., Loscher W. Valproic acid and metabolites: Pharmacological and toxicological studies. Epilepsia. 1984;25(Suppl 1):14–22. doi: 10.1111/j.1528-1157.1984.tb05632.x. [DOI] [PubMed] [Google Scholar]
- 483.Weber W.W., Hein D.W. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet. 1979;4:401–422. doi: 10.2165/00003088-197904060-00001. [DOI] [PubMed] [Google Scholar]
